AMNEAL PHARMACEUTICALS, INC., 10-Q filed on 11/9/2026
Quarterly Report
v3.26.3
Cover - shares
9 Months Ended
Sep. 30, 2026
Oct. 30, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2026  
Document Transition Report false  
Entity File Number 001-38485  
Entity Registrant Name Amneal Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 93-4225266  
Entity Address, Address Line One 400 Crossing Boulevard,  
Entity Address, City or Town Bridgewater  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08807  
City Area Code 908  
Local Phone Number 947-3120  
Title of 12(b) Security Class A Common Stock, par value $0.01 per share  
Trading Symbol AMRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   348,412,726
Entity Central Index Key 0001723128  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.26.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Net revenue $ 862,684 $ 784,513 $ 2,381,400 $ 2,204,441
Cost of goods sold 528,566 510,539 1,392,661 1,388,323
Gross profit 334,118 273,974 988,739 816,118
Selling, general and administrative 139,645 137,815 427,227 380,369
Research and development 68,374 63,352 145,774 151,356
Intellectual property legal development expenses 2,193 2,437 5,822 6,221
Acquisition and integration costs 22,320 0 35,073 0
Restructuring and other charges 936 143 2,140 1,738
Change in fair value of contingent consideration (6,000) 0 (6,000) 0
Charges for property losses and associated expenses 5,369 0 5,369 0
Charges (credit) related to legal matters, net 6,497 0 15,248 (390)
Other operating income (631) (117) (8,870) (5,239)
Operating income 95,415 70,344 366,956 282,063
Other (expense) income:        
Interest expense, net (58,913) (62,814) (167,317) (184,854)
Foreign exchange (loss) gain, net (3,174) (3,431) (12,924) 9,072
Loss on refinancing (5,760) (31,365) (9,270) (31,365)
(Increase) decrease in tax receivable agreement liability (12,992) 20,808 (13,098) 5,701
Other income, net 481 1,235 1,876 3,357
Total other expense, net (80,358) (75,567) (200,733) (198,089)
Income (loss) before income taxes 15,057 (5,223) 166,223 83,974
Provision for (benefit from) income taxes 2,751 (23,355) 6,303 5,614
Net income 12,306 18,132 159,920 78,360
Less: Net income attributable to non-controlling interests (19,762) (15,763) (47,458) (41,379)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests (7,456) 2,369 112,462 36,981
Accretion of redeemable non-controlling interests (14,239) 0 (14,239) 0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:        
Basic (in dollars per share) $ (0.06) $ 0.01 $ 0.30 $ 0.12
Diluted (in dollars per share) $ (0.06) $ 0.01 $ 0.29 $ 0.11
Weighted-average common shares outstanding:        
Basic (in shares) 335,733 314,168 323,724 312,998
Diluted (in shares) 335,733 324,754 335,233 323,704
v3.26.3
Consolidated Statements of Comprehensive (Loss) Income - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Statement of Other Comprehensive Income [Abstract]        
Net income $ 12,306 $ 18,132 $ 159,920 $ 78,360
Less: Net income attributable to non-controlling interests (19,762) (15,763) (47,458) (41,379)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests (7,456) 2,369 112,462 36,981
Accretion of redeemable non-controlling interests (14,239) 0 (14,239) 0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. (21,695) 2,369 98,223 36,981
Other comprehensive (loss) income:        
Foreign currency translation adjustments arising during the period (3,428) (9,088) (13,332) (15,648)
Unrealized gain (loss) on cash flow hedge, net of tax of $0 17,563 (3,526) 28,019 (23,011)
Reclassification of cash flow hedge to earnings, net of tax of $0 2,942 4,162 8,730 (1,714)
Other Comprehensive Income, Other, Net of Tax 505 0 4,228 0
Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. 17,582 (8,452) 27,645 (40,373)
Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (4,113) $ (6,083) $ 125,868 $ (3,392)
v3.26.3
Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Statement of Comprehensive Income [Abstract]        
Tax on unrealized gain (loss) on cash flow hedge $ 0 $ 0 $ 0 $ 0
Taxes on reclassification of cash flow hedge to earnings 0 0 0 0
Taxes on other $ 0 $ 0 $ 0 $ 0
v3.26.3
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 157,399 $ 282,029
Restricted cash 14,174 28,842
Inventories 707,956 606,302
Prepaid expenses and other current assets 196,769 98,395
Total current assets 2,095,018 1,911,181
Property, plant and equipment, net 572,634 442,950
Goodwill 772,473 595,470
Intangible assets, net 1,551,255 563,498
Financing lease right-of-use assets 63,255 53,328
Other assets 122,807 57,805
Total assets 5,267,221 3,678,280
Current liabilities:    
Current portion of liabilities for legal matters 27,534 43,256
Revolving credit facility 180,000 0
Current portion of long-term debt, net 23,933 6,761
Current portion of financing lease liabilities 3,811 3,442
Contingent consideration - related party - short term 59,000 0
Total current liabilities 1,119,837 881,633
Long-term debt, net 2,915,501 2,565,115
Financing lease liabilities 65,588 54,927
Liabilities for legal matters - long term 71,663 71,819
Contingent consideration - related party - long term 324,000 0
Total long-term liabilities 3,506,674 2,790,684
Commitments and contingencies (Notes 4, 18 and 20)
Redeemable non-controlling interests 109,453 77,292
Stockholders’ Equity (Deficiency)    
Preferred stock, $0.01 par value, 2,000 shares authorized at both September 30, 2026 and December 31, 2025; none issued at both September 30, 2026 and December 31, 2025 0 0
Additional paid-in capital 1,047,639 571,794
Stockholders’ accumulated deficit (436,782) (535,005)
Accumulated other comprehensive loss (83,084) (110,729)
Total Amneal Pharmaceuticals, Inc. stockholders’ equity (deficiency) 531,257 (70,794)
Non-controlling interests 0 (535)
Total stockholders’ equity (deficiency) 531,257 (71,329)
Total liabilities and stockholders’ equity (deficiency) 5,267,221 3,678,280
Common Class A    
Stockholders’ Equity (Deficiency)    
Common stock 3,484 3,146
Common Class B    
Stockholders’ Equity (Deficiency)    
Common stock 0 0
Nonrelated Party    
Current assets:    
Receivables 1,016,844 895,143
Operating lease right-of-use assets 69,760 38,832
Current liabilities:    
Accounts payable and accrued expenses 788,831 761,316
Current portion of operating lease liabilities 14,417 8,668
Operating lease liabilities 59,612 33,233
Related party payables - long term 37,797 32,263
Related Party    
Current assets:    
Receivables 1,876 470
Operating lease right-of-use assets 20,019 15,216
Current liabilities:    
Accounts payable and accrued expenses 18,913 55,485
Current portion of operating lease liabilities 3,398 2,705
Operating lease liabilities 16,635 14,195
Related party payables - long term $ 15,878 $ 19,132
v3.26.3
Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Thousands
Sep. 30, 2026
Dec. 31, 2025
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000 2,000
Preferred stock, shares issued (in shares) 0 0
Common Class A    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 900,000 900,000
Common stock, shares issued (in shares) 348,368 314,565
Common Class B    
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 300,000 300,000
Common stock, shares issued (in shares) 0 0
v3.26.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net income $ 159,920 $ 78,360
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 144,250 174,345
Unrealized foreign currency loss (gain) 13,571 (8,606)
Amortization of debt issuance costs and discount 12,141 18,716
Reclassification of cash flow hedge 8,730 (1,713)
Loss on refinancing 9,270 31,365
Intangible asset impairment charges 975 22,784
Research and development equipment impairment charges 13,832 0
Non-cash property losses 5,035 0
Change in fair value of contingent consideration (6,000) 0
Stock-based compensation 29,723 23,751
Inventory provision 64,981 59,326
Other operating charges and credits, net 4,689 3,575
Changes in assets and liabilities:    
Trade accounts receivable, net (122,423) (110,228)
Inventories (158,346) (66,846)
Prepaid expenses, other current assets and other assets (113,073) (20,173)
Related party receivables 203 (830)
Accounts payable, accrued expenses and other liabilities 17,590 2,744
Related party payables (34,756) 3,107
Net cash provided by operating activities 50,312 209,677
Cash flows from investing activities:    
Acquisition of Kashiv, net of cash and restricted cash acquired (421,047) 0
Purchases of property, plant and equipment (70,659) (48,290)
Acquisition of intangible assets (96,603) (12,514)
Deposits for future acquisition of property, plant and equipment (28,376) (7,384)
Proceeds from sale of property, plant and equipment 0 1,379
Net cash used in investing activities (616,685) (66,809)
Cash flows from financing activities:    
Payments of principal on debt, revolving credit facilities and financing leases (293,172) (2,805,384)
Proceeds from issuance of debt 529,853 2,694,750
Payments of deferred financing and refinancing costs (7,549) (74,973)
Borrowings on revolving credit facilities 280,000 218,000
Proceeds from exercise of stock options 516 1,407
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting (44,696) (21,957)
Tax and other distributions to non-controlling interests (29,571) (38,825)
Proceeds from alliance party 510 5,572
Acquisition of non-controlling interest (400) 0
Net cash provided by (used in) financing activities 435,491 (21,410)
Effect of foreign exchange rate on cash (1,804) (1,471)
Net decrease in cash, cash equivalents, and restricted cash (132,686) 119,987
Cash, cash equivalents, and restricted cash - beginning of period 312,939 118,420
Cash, cash equivalents, and restricted cash - end of period 180,253 238,407
Cash and cash equivalents - end of period 157,399 201,249
Restricted cash - end of period 14,174 34,727
Long-term restricted cash included in other assets - end of period 8,680 2,431
Cash, cash equivalents, and restricted cash - end of period 180,253 238,407
Supplemental disclosure of cash flow information:    
Cash paid for interest 151,671 156,447
Cash paid, net for income taxes 4,558 17,576
Supplemental disclosure of non-cash investing and financing activity:    
Contingent consideration for acquisition - related party 389,000 0
Class A common stock issued in connection with the Kashiv Acquisition 491,610 0
Acquisition of product rights and licenses 602 411
Loan for land purchase - related party $ 0 $ 482
v3.26.3
Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Class A Common Stock
Additional Paid-in Capital
Stockholders’ Accumulated Deficit
Accumulated Other Comprehensive Loss
Non- Controlling Interests
Shares beginning balance (in shares) at Dec. 31, 2024   309,881        
Stockholders' equity beginning balance at Dec. 31, 2024 $ (109,512) $ 3,099 $ 560,206 $ (607,062) $ (65,510) $ (245)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 36,729     36,981   (252)
Foreign currency translation adjustments (15,648)       (15,648)  
Stock-based compensation 23,751   23,751      
Exercise of stock options (in shares)   512        
Exercise of stock options 1,407 $ 5 1,402      
Shares issued upon vesting of stock-based compensation awards (in shares)   3,918        
Shares issued upon vesting of stock-based compensation awards (21,957) $ 39 (21,996)      
Unrealized gain (loss) on cash flow hedge, net of tax (23,011)       (23,011)  
Reclassification of cash flow hedge to earnings, net of tax (1,714)       (1,714)  
Shares ending balance (in shares) at Sep. 30, 2025   314,311        
Stockholders' equity ending balance at Sep. 30, 2025 (109,955) $ 3,143 563,363 (570,081) (105,883) (497)
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2024 64,974          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net income (loss) 41,631          
Tax and other distributions, net (38,825)          
Redeemable Non-Controlling Interests, ending balance at Sep. 30, 2025 67,780          
Shares beginning balance (in shares) at Jun. 30, 2025   314,043        
Stockholders' equity beginning balance at Jun. 30, 2025 (112,533) $ 3,140 554,623 (572,450) (97,431) (415)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 2,287     2,369   (82)
Foreign currency translation adjustments (9,088)       (9,088)  
Stock-based compensation 8,219   8,219      
Exercise of stock options (in shares)   238        
Exercise of stock options 653 $ 3 650      
Shares issued upon vesting of stock-based compensation awards (in shares)   30        
Shares issued upon vesting of stock-based compensation awards (129) $ 0 (129)      
Unrealized gain (loss) on cash flow hedge, net of tax (3,526)       (3,526)  
Reclassification of cash flow hedge to earnings, net of tax 4,162       4,162  
Shares ending balance (in shares) at Sep. 30, 2025   314,311        
Stockholders' equity ending balance at Sep. 30, 2025 (109,955) $ 3,143 563,363 (570,081) (105,883) (497)
Redeemable Non-Controlling Interests, beginning balance at Jun. 30, 2025 65,802          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net income (loss) 15,845          
Tax and other distributions, net (13,867)          
Redeemable Non-Controlling Interests, ending balance at Sep. 30, 2025 67,780          
Shares beginning balance (in shares) at Dec. 31, 2025   314,565        
Stockholders' equity beginning balance at Dec. 31, 2025 (71,329) $ 3,146 571,794 (535,005) (110,729) (535)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 112,427     112,462   (35)
Foreign currency translation adjustments (13,332)       (13,332)  
Stock-based compensation 29,723   29,723      
Exercise of stock options (in shares)   101        
Exercise of stock options 516 $ 1 515      
Shares issued upon vesting of stock-based compensation awards (in shares)   4,760        
Shares issued upon vesting of stock-based compensation awards (44,696) $ 48 (44,744)      
Unrealized gain (loss) on cash flow hedge, net of tax 28,019       28,019  
Reclassification of cash flow hedge to earnings, net of tax 8,730       8,730  
Acquisition of non-controlling interests (400)   (970)     570
Accretion of redeemable non-controlling interests (14,239)     (14,239)    
Shares issued in connection with the acquisition of Kashiv (in shares)   28,942        
Shares issued in connection with the acquisition of Kashiv 491,610 $ 289 491,321      
Other, net of tax 4,228       4,228  
Shares ending balance (in shares) at Sep. 30, 2026   348,368        
Stockholders' equity ending balance at Sep. 30, 2026 531,257 $ 3,484 1,047,639 (436,782) (83,084) 0
Redeemable Non-Controlling Interests, beginning balance at Dec. 31, 2025 77,292          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net income (loss) 47,493          
Tax and other distributions, net (29,571)          
Accretion of redeemable non-controlling interests 14,239          
Redeemable Non-Controlling Interests, ending balance at Sep. 30, 2026 109,453          
Shares beginning balance (in shares) at Jun. 30, 2026   319,330        
Stockholders' equity beginning balance at Jun. 30, 2026 33,024 $ 3,193 545,584 (415,087) (100,666) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) (7,456)     (7,456)   0
Foreign currency translation adjustments (3,428)       (3,428)  
Stock-based compensation 10,515   10,515      
Exercise of stock options (in shares)   72        
Exercise of stock options 436 $ 1 435      
Shares issued upon vesting of stock-based compensation awards (in shares)   24        
Shares issued upon vesting of stock-based compensation awards (215) $ 1 (216)      
Unrealized gain (loss) on cash flow hedge, net of tax 17,563       17,563  
Reclassification of cash flow hedge to earnings, net of tax 2,942       2,942  
Accretion of redeemable non-controlling interests (14,239)     (14,239)    
Shares issued in connection with the acquisition of Kashiv (in shares)   28,942        
Shares issued in connection with the acquisition of Kashiv 491,610 $ 289 491,321      
Other, net of tax 505       505  
Shares ending balance (in shares) at Sep. 30, 2026   348,368        
Stockholders' equity ending balance at Sep. 30, 2026 531,257 $ 3,484 $ 1,047,639 $ (436,782) $ (83,084) $ 0
Redeemable Non-Controlling Interests, beginning balance at Jun. 30, 2026 83,956          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net income (loss) 19,762          
Tax and other distributions, net (8,504)          
Accretion of redeemable non-controlling interests 14,239          
Redeemable Non-Controlling Interests, ending balance at Sep. 30, 2026 $ 109,453          
v3.26.3
Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) (Parenthetical) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Statement of Stockholders' Equity [Abstract]        
Tax on unrealized gain (loss) on cash flow hedge $ 0 $ 0 $ 0 $ 0
Tax on reclassification of cash flow hedge to earnings 0 $ 0 0 $ 0
Taxes on other $ 0   $ 0  
v3.26.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The interim unaudited consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission and U.S. generally accepted accounting principles (“U.S. GAAP”) for interim reporting. These financial statements include all adjustments that in the opinion of management are necessary for a fair presentation of the financial position, results of operations, and cash flows of Amneal Pharmaceuticals, Inc. (the “Company”) for the periods presented. However, these financial statements do not include all information and accompanying notes required for annual financial statements prepared in accordance with U.S. GAAP. The interim unaudited consolidated financial statements should be read in conjunction with the audited annual financial statements included in the Company’s 2025 Annual Report on Form 10-K.
Use of Estimates
The preparation of financial statements requires the Company’s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
v3.26.3
Acquisition
9 Months Ended
Sep. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Acquisition Acquisition
Kashiv BioSciences, LLC Acquisition
On April 21, 2026, the Company entered into a definitive agreement (the “Purchase Agreement”) for Amneal to acquire 100% of the outstanding membership interests in Kashiv BioSciences, LLC (a related party, see Note 20. Related Party Transactions) (“Kashiv”) in a transaction with consideration that included $375.0 million of cash and 28,942,108 shares of Class A common stock of the Company at closing, subject to customary purchase price adjustments for cash (the “Kashiv Acquisition”). Consideration for the transaction also included up to $350.0 million in potential contingent payments based on the achievement of certain regulatory milestones in the United States and potential contingent royalties equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty periods during the twelve-year period following the closing of the transaction. Kashiv is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars.
On August 10, 2026, the Company completed the Kashiv Acquisition for a preliminary purchase price of $1.3 billion. Kashiv’s operating results have been included in the Company’s consolidated financial statements since the acquisition date. The cash
portion of the consideration was funded through borrowings under the Company’s credit facilities (refer to Note 14. Debt for additional information). The Kashiv Acquisition was accounted for as a business combination under the acquisition method of accounting, with Amneal as the accounting acquirer.
The preliminary fair value of consideration transferred is summarized as follows (in thousands):
Cash consideration (1)
$266,066
Equity consideration (2)
491,610
Fair value of contingent consideration – milestone payments (3)
137,000
Fair value of contingent consideration – royalty payments (4)
252,000
Repayment of certain Kashiv debt obligations (5)
162,180
Receivable from sellers related to purchase price adjustment (6)
(1,814)
Settlement of pre-existing relationship (7)
(4,556)
Preliminary fair value of consideration transferred$1,302,486
(1)The cash consideration paid at closing of $266.1 million reflects the initial cash consideration of $375.0 million, less $180.0 million of indebtedness and $3.0 million of transaction expenses, plus $3.9 million of estimated closing cash, $66.7 million of working capital adjustments and $3.5 million of prepayment adjustments, each as determined pursuant to the terms of the Purchase Agreement. Certain amounts remain subject to customary post-closing adjustments.
(2)The Company issued 28.9 million shares of its Class A common stock to the sellers of Kashiv. The fair value of the equity consideration was based on the $17.88 closing price of the Company’s Class A common stock on NASDAQ on August 10, 2026, adjusted by a 5% discount for lack of marketability reflecting temporary transfer restrictions associated with the then-unregistered shares.
(3)The sellers of Kashiv are eligible to receive up to $350.0 million in contingent milestone payments upon the achievement of certain regulatory milestones in the United States for up to six designated Kashiv product candidates (consisting of up to $250.0 million for the first tranche of designated products and up to $100.0 million for the second tranche of designated products). The preliminary fair value of the contingent consideration for milestone payments on the acquisition date of approximately $137.0 million was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, probability of achievement of milestones, and projected year of payments. Refer to Note 16. Fair Value Measurements for additional information on the methodology and determination of this liability.
(4)The sellers of Kashiv are also eligible to receive, during the 12-year period following the acquisition date, royalty payments equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty period. The preliminary fair value of the contingent consideration for royalty payments on the acquisition date of approximately $252.0 million was based on significant Level 3 inputs that were not observable in the market. Key assumptions included projected future gross profits for the underlying products, the timing and probability of expected payments, and the discount rate applied to the estimated future cash flows. Refer to Note 16. Fair Value Measurements for additional information on the methodology and determination of this liability.
(5)Represents amounts paid at closing to repay certain debt obligations of Kashiv, including related prepayment amounts.
(6)Represents an estimated amount due from the sellers related to post-closing purchase price adjustments.
(7)The pre-existing balances between the Company and Kashiv were effectively settled upon completion of the acquisition.

The initial accounting for the acquisition remains incomplete, primarily related to the valuation of certain acquired assets and liabilities, including working capital, property, plant and equipment, intangible assets and contingent consideration, due to the
proximity of the acquisition date to the balance sheet date of September 30, 2026. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):
Preliminary Fair Values as of
August 10, 2026
Cash and cash equivalents$3,111
Inventories (1)
22,215
Prepaid expenses and other current assets12,034
Related party receivables234
Property, plant and equipment (2)
111,584
Goodwill179,478
Intangible assets1,003,000
Operating lease right-of-use assets26,798
Operating lease right-of-use assets - related party (3)
7,143
Other assets (4)
14,299
Total assets acquired1,379,896
Accounts payable and accrued expenses28,838
Current portion of operating lease liabilities4,605
Current portion of operating lease liabilities - related party412
Related party payables - short term64
Long-term debt, net15,137
Operating lease liabilities22,687
Operating lease liabilities - related party4,768
Other long-term liabilities899
Total liabilities assumed77,410
Preliminary fair value of consideration transferred$1,302,486
(1)Includes a $6.5 million inventory fair value step-up adjustment, which will be recognized in cost of goods sold as the related inventory is sold.
(2)Includes a $10.9 million fair value step-up adjustment for acquired property, plant and equipment from its historical carrying value to its preliminary fair value, which will be recognized over the remaining service lives of the assets as depreciation expense.
(3)Includes a $2.0 million adjustment to reflect favorable lease terms relative to market.
(4)Includes $4.1 million of long-term restricted cash.
The preliminary fair values and estimated useful lives of identifiable intangible assets acquired as of August 10, 2026 were as follows (in thousands):
Preliminary Fair ValueWeighted-Average
Useful Life
(in years)
In-process research and development (“IPR&D”) (1)
$963,000
Indefinite (2)
Marketed product rights40,0009.0
Fair value of identifiable intangible assets acquired$1,003,000
(1)During September 2026, following the regulatory approval and launch of lanreotide, the related acquired IPR&D was reclassified to marketed product rights and began amortizing over an estimated useful life of approximately five years.
(2)IPR&D assets are considered indefinite‑lived until completion or abandonment of the related projects and are not amortized during the development period. Upon commercialization, the Company will determine a useful life and begin amortization.
The preliminary fair value of the identifiable intangible assets was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the preliminary purchase price were based on management’s best estimates as of the closing date of the Kashiv Acquisition on August 10, 2026.
Some of the more significant assumptions inherent in the development of these asset valuations included projected revenues and revenue growth rates, estimated EBITDA margins, probability of success, and the discount rates applied to the projected cash flows. In developing these assumptions, management considered factors such as expected net cash flows for each asset or product, including anticipated revenues and associated costs, the risks and uncertainties associated with regulatory and commercial success, the expected lifecycle of each asset, and competitive and market trends. These assumptions reflect management's best estimates as of the acquisition date and involve significant judgment and uncertainty. Changes in the underlying assumptions could result in materially different fair value estimates; accordingly, actual results may vary significantly from estimated results.
The preliminary purchase price allocation remains subject to change as additional information regarding the fair values of assets acquired and liabilities assumed becomes available during the measurement period. Such changes could be material given the proximity of the acquisition date to September 30, 2026. Adjustments to the preliminary fair values of the net assets acquired could affect the Company’s consolidated financial statements in future periods.
Goodwill is measured as the excess of the preliminary fair value of the consideration transferred over the preliminary fair value of identifiable assets acquired, net of liabilities assumed. Goodwill primarily reflects the value of the assembled workforce, strategic positioning in the biosimilars market that Amneal anticipates capturing with the acquired platform, expected synergies and future revenue growth opportunities not attributable to currently identifiable assets, all of which was allocated to the Company’s Affordable Medicines segment.
The transaction was treated as an asset purchase for income tax purposes. The tax bases of the acquired assets and liabilities approximated their amounts recognized for financial reporting purposes at the acquisition date; accordingly, no deferred tax assets or liabilities were initially recognized with respect to those assets and liabilities. The goodwill, acquired intangible assets (marketed product rights and IPR&D), and tangible assets are expected to be fully deductible for income tax purposes.
For the three and nine months ended September 30, 2026, acquisition-related costs incurred and expensed in connection with the Kashiv Acquisition were $19.0 million and $31.7 million, respectively, and were recorded in acquisition and integration costs in the consolidated statements of operations.
For the three and nine months ended September 30, 2026, Kashiv contributed total net revenue of approximately $1.2 million and operating loss of $28.4 million to the Company’s consolidated results of operations.
Unaudited Pro Forma Information
The unaudited pro forma combined results of operations for the three and nine months ended September 30, 2026 and 2025
(assuming the closing of the Kashiv Acquisition occurred on January 1, 2025) were as follows (in thousands):

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net revenue$862,918$793,555$2,386,897$2,216,607
Net income (loss)$8,411$(22,748)$61,380$(43,119)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest$(11,351)$(38,511)$13,922$(84,498)
The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the Kashiv Acquisition closed on January 1, 2025. Furthermore, the pro forma results do not purport to project the future results of operations of the Company.
Adjustments to arrive at the unaudited pro forma information primarily reflect: (i) the elimination of intercompany transactions between Amneal and Kashiv, including the related impacts on net revenue, cost of goods sold and research and development (“R&D”) expenses; (ii) increases to cost of goods sold resulting primarily from amortization of acquired finite-lived intangible assets recognized in connection with the acquisition; (iii) a net increase in interest expense resulting from borrowings under the existing Term Loan due 2032 and Revolving Credit Facility used to finance the acquisition, partially offset by the elimination of historical interest expense associated with Kashiv term loan repaid on the acquisition date; and (iv) the removal of non-recurring transaction costs recognized in the historical financial statements and the presentation of such costs as if incurred on January 1, 2025. These adjustments are presented net of the related income tax effects.
v3.26.3
Revenue Recognition
9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. The majority of the Company’s revenue is recognized from shipping products to customers. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
License Agreements
Refer to Note 4. Alliance and Collaboration in the Company’s 2025 Annual Report on Form 10-K for further information related to revenue recognition associated with license agreements.
Concentration of Revenue
The following table summarizes revenues from each of the Company’s customers that individually accounted for 10% or more of its total net revenue in any of the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Customer A25 %23 %24 %24 %
Customer B16 %14 %16 %15 %
Customer C21 %22 %21 %21 %
Customer D
7 %10 %8 %9 %
Disaggregated Revenue
Effective August 10, 2026, Kashiv’s results are included within the Company’s Affordable Medicines segment. The Company’s significant dosage forms within its Affordable Medicines segment, therapeutic classes within its Specialty segment, and sales channels within its AvKARE segment, each determined based on net revenue for the three and nine months ended September 30, 2026 and 2025, are presented below (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Affordable Medicines
Oral solid$207,517 $180,460 $553,789 $537,675 
Transdermal68,066 47,599 209,067 131,372 
Auto-Injector65,163 78,940 169,289 193,694 
Injectable53,805 54,368 160,526 123,802 
Biosimilar77,710 17,009 129,139 70,797 
Oral liquid9,092 16,415 31,555 57,842 
Other dosage forms (1)
60,841 59,662 189,047 184,269 
Subtotal dosage forms542,194 454,453 1,442,412 1,299,451 
International4,915 6,288 17,847 9,423 
Total Affordable Medicines net revenue547,109 460,741 1,460,259 1,308,874 
Specialty
Central nervous system96,177 77,631 274,904 228,666 
Hormonal / allergy43,148 37,685 121,179 107,302 
Other therapeutic classes9,449 9,924 35,251 25,112 
Subtotal therapeutic classes148,774 125,240 431,334 361,080 
License agreement1,488 — 1,488 500 
Total Specialty net revenue150,262 125,240 432,822 361,580 
AvKARE
Distribution92,905 96,216 268,984 300,774 
Government label53,385 87,755 163,541 183,313 
Institutional10,012 5,853 31,943 26,994 
Other9,011 8,708 23,851 22,906 
Total AvKARE net revenue165,313 198,532 488,319 533,987 
Total net revenue$862,684 $784,513 $2,381,400 $2,204,441 
(1)Includes net revenue from sales of transmucosal, ophthalmic, topical, nasal and inhalation dosage forms.
A rollforward of the major categories of sales-related deductions for the nine months ended September 30, 2026 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2025$801,186 $40,992 $179,471 $119,486 
Provision related to sales recorded in the period3,161,376 107,663 60,770 135,010 
Credits/payments issued during the period(3,427,057)(116,413)(48,728)(184,184)
Balance at September 30, 2026$535,505 $32,242 $191,513 $70,312 
v3.26.3
Alliance and Collaboration
9 Months Ended
Sep. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Alliance and Collaboration Alliance and Collaboration
The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements. These agreements generally obligate the Company to provide R&D services over multiple periods.
Except as disclosed below, as of and for the three and nine months ended September 30, 2026, there were no material changes to our alliance and collaboration agreements as described and defined in Note 4. Alliance and Collaboration in the Company’s 2025 Annual Report on Form 10-K.
The following table summarizes certain amounts recognized in the Company’s consolidated statements of operations related to alliance and collaboration agreements for the three and nine months ended September 30, 2026 and 2025 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
PartyCaption in Statement of Operations2026202520262025
Orion Corporation
Research and development (1)
$(776)$(912)$(1,883)$(2,677)
Orion Corporation
Research and development (2)
$(197)$(372)$(818)$(1,131)
Pfizer Inc. (formerly Metsera, Inc.)
Other operating income (3)
$— $— $(6,877)$— 
Pfizer Inc. (formerly Metsera, Inc.)
Net revenue (4)
$— $245 $— $2,218 
Zambon Biotech S.A.
Net revenue (5)
$1,488 $— $1,488 $— 
(1)Deferred income was recognized as a reduction to R&D expense as services were performed under the Orion Agreement.
(2)Reimbursable R&D services performed under the Orion Agreement were recorded as a reduction to R&D expense.
(3)Gain from derecognizing financing obligation (refer to the Pfizer Collaboration Agreement section below).
(4)Development activities performed on behalf of Pfizer, Inc. on a cost plus margin basis are recorded as net revenue.
(5)Net revenue was recognized for achievement of a regulatory approval milestone.
The following table summarizes certain balances recognized in the Company’s consolidated balance sheets related to alliance and collaboration agreements as of September 30, 2026 and December 31, 2025 (in thousands):
PartyCaption in Balance SheetSeptember 30, 2026December 31, 2025
Orion Corporation
Accounts payable and accrued expenses (1)
$3,445 $4,811 
Orion Corporation
Other long-term liabilities (1)
$296 $814 
Zambon Biotech S.A.
Other long-term liabilities (1)
$2,725 $2,530 
Zambon Biotech S.A.
Accounts payable and accrued expenses (1)
$641 $— 
mAbxience S.L.
Accounts payable and accrued expenses (2)
$— $7,500 
Pfizer Inc. (formerly Metsera, Inc.)
Prepaid expenses and other current assets (3)
$— $321 
Pfizer Inc. (formerly Metsera, Inc.)
Other long-term liabilities (4)
$22,415 $9,378 
(1)Comprised of deferred income as of September 30, 2026 and December 31, 2025.
(2)Comprised of an accrued milestone as of December 31, 2025 for a Food and Drug Administration (“FDA”) approval.
(3)Comprised primarily of unbilled receivables for R&D services performed as of December 31, 2025.
(4)Comprised of construction costs contributed, as defined in the Company’s collaboration agreement with Pfizer Inc. (“Pfizer”). As of September 30, 2026, the funding received from Pfizer represented a contract obligation for future manufacturing services (deferred income). As of December 31, 2025, the funding received from Pfizer was allocated between two performance obligations: (i) a financing obligation in accordance with ASC 470, Debt of $6.4 million and (ii) a contract obligation for future manufacturing services of $3.0 million (refer to the Pfizer Collaboration Agreement section below).
New Developments in 2026
Pfizer Collaboration Agreement
On November 13, 2025, Metsera, Inc. (“Metsera”) was acquired by Pfizer. On January 30, 2026, Pfizer exercised its rights under the change-in-control provision in the Metsera collaboration agreement with the Company to shorten the agreement’s term from seven years to four years from the date of first commercial sale. As a result, the Company’s rebate and construction cost reimbursement obligations to Pfizer have been eliminated. Pfizer’s cost sharing commitment of up to $100 million for construction costs and all other terms of the agreement remain unchanged.
In connection with the notice from Pfizer, the Company recognized a gain of $6.9 million in other operating income for the nine months ended September 30, 2026 to derecognize the financing obligation previously recognized in accordance with ASC 470, Debt through the date of the notice. The Company will classify all future proceeds received from Pfizer for construction costs contributed as a contract obligation for future manufacturing services (recorded as deferred income within other long‑term liabilities on the consolidated balance sheet). As of September 30, 2026, no commercial products have been launched under this collaboration agreement. Refer to Note 15. Other Long-Term Liabilities for additional information.
MSN Laboratories Private Limited Supply and Distribution Agreement
On April 2, 2026, the Company entered into a supply and distribution agreement with MSN Laboratories Private Limited (“MSN”) for the exclusive distribution of generic mirabegron extended‑release tablets in the United States and its territories (the “MSN agreement”). Mirabegron is a generic, AB-rated version of the reference listed drug, Myrbetriq®. In connection with the MSN agreement, the Company made an upfront cash payment of $75.0 million in April 2026, which was capitalized as a product rights intangible asset and is being amortized to cost of sales over its estimated useful life of five years following the commercial launch of the product in the second quarter of 2026. Additionally, the Company will pay a per‑unit fee and profit‑sharing to MSN based on product sales. MSN is responsible for the commercial manufacture and supply of the finished product and the Company is responsible for the marketing, promotion, and sale of the product.
Adalvo License and Supply Agreement – Tirzepatide
On May 13, 2026, the Company entered into a License and Supply Agreement with Adalvo to develop, register and commercialize two generic tirzepatide products in the U.S. Pursuant to the agreement, the Company received exclusive rights to Adalvo’s regulatory dossiers and related intellectual property for use in obtaining U.S. regulatory approvals for the products. The Company is responsible for regulatory filings, commercialization and distribution, while Adalvo is responsible for development, manufacturing and supply of the products. The agreement provides for development, regulatory and commercial milestone payments of up to $21.0 million, including payments upon regulatory submissions and acceptance, regulatory approvals, product launches and achievement of a specified cumulative net sales threshold. The Company will share a portion of net profits from product sales with Adalvo, after deduction of agreed-upon costs, pursuant to the terms of the agreement. Profit share amounts are calculated and settled on a quarterly basis.
During the nine months ended September 30, 2026, the Company recorded $3.0 million of R&D expense related to the achievement of regulatory milestones under the agreement (submission of an Abbreviated New Drug Application (“ANDA”) and subsequent acceptance by the FDA) for each product.
mAbxience Biosimilar Licensing and Supply Agreement – Denosumab
On May 26, 2026, the Company entered into a supply agreement with mAbxience S.L. (“mAbxience”) to establish supply pricing for Boncresa® and Oziltus® (denosumab biosimilars referencing Prolia® and XGEVA®, respectively). The supply agreement is an addition to the Company’s existing licensing arrangement with mAbxience dated October 12, 2023, as previously described in Note 4. Alliance and Collaboration in the Company’s 2025 Annual Report on Form 10-K.
In connection with the execution of the supply agreement, the Company incurred a one-time signing fee of $6.0 million payable to mAbxience, which was capitalized as an intangible asset during the three months ended June 30, 2026. The signing fee was paid during the three months ended September 30, 2026. The intangible asset will be amortized to cost of sales over its estimated useful life of five years, with amortization commencing upon commercial launch of the products.
Alvotech hf. License Agreement
In connection with the closing of the Kashiv Acquisition on August 10, 2026, the Company acquired a product licensing and supply agreement with Alvotech hf. (“Alvotech”) pursuant to which Alvotech has exclusive rights to obtain regulatory approval for and commercialize a biosimilar to XOLAIR® (omalizumab) in the European Union, the United Kingdom, Australia, Canada
and New Zealand. Under the agreement, the Company is responsible for certain R&D activities and dossier-related support, while Alvotech is responsible for regulatory approval, commercialization, marketing and sales activities within the licensed territories. The agreement provides for potential future development, regulatory and commercial milestone payments of up to $25.0 million and royalties based on net sales of the licensed product, subject to specified deductions. No milestone revenue was recognized under the agreement during the period from the acquisition date through September 30, 2026.
Intas Pharmaceuticals Limited License Agreement
In connection with the closing of the Kashiv Acquisition on August 10, 2026, the Company acquired an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) pursuant to which Intas has the commercialization rights of lanreotide in Europe and India. The agreement provides for potential future development, regulatory, launch and sales-based milestone payments totaling up to approximately $23.5 million. Upon regulatory approval, the Company will be responsible for manufacturing and supplying drug substance to Intas. No milestone revenue was recognized under the agreement during the period from the acquisition date through September 30, 2026.
v3.26.3
Income Taxes
9 Months Ended
Sep. 30, 2026
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Provision for (Benefit from) Income Taxes
Set forth in the following table is the Company’s provision for (benefit from) income taxes (in thousands) and effective tax rate:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Provision for (benefit from) income taxes$2,751 $(23,355)$6,303 $5,614 
Effective tax rate18.3 %447.2 %3.8 %6.7 %
For the three and nine months ended September 30, 2026, period-over-period changes in the provision for (benefit from) income taxes and effective tax rate were primarily driven by changes in the level and jurisdictional mix of earnings, the impact of the One Big Beautiful Bill Act (enacted in July 2025), and, for the nine months ended September 30, 2026, discrete tax benefits related to share-based compensation recognized in the current year period.
Tax Receivable Agreement
The following table summarizes the Company’s tax receivable agreement (“TRA”) (in thousands):
Statements of Operations
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Increase (decrease) in tax receivable agreement liability$12,992 $(20,808)$13,098 $(5,701)
Balance Sheet
September 30, 2026December 31, 2025
Tax receivable agreement liability - short term (1)
$16,323 $38,832 
Tax receivable agreement liability - long term (1)
15,432 18,656 
Total$31,755 $57,488 
(1) Refer to Note 20. Related Party Transactions.
Refer to Note 5. Income Taxes in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s TRA. During the nine months ended September 30, 2026, the Company made payments of $38.8 million associated with the TRA liability for the 2024 tax year.
Contingent Tax Receivable Agreement Liability
The Company had an unrecorded contingent TRA liability of $116.0 million as of September 30, 2026. If utilization of the
Company’s deferred tax assets becomes more-likely-than-not in the future and the related tax benefits are recognized in income, the unrecorded contingent TRA liability will be recorded through charges in the Company’s consolidated statements of operations.
v3.26.3
(Loss) Earnings per Share
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
(Loss) Earnings per Share (Loss) Earnings per Share
The computation of basic and diluted (loss) earnings per share was as follows (in thousands, except per share amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Numerator:
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.
$(21,695)$2,369 $98,223 $36,981 
Denominator:
Weighted-average shares outstanding - basic335,733 314,168 323,724 312,998 
Effect of dilutive securities:
Stock options— 882 767 981 
Restricted stock units— 4,129 4,192 4,303 
Performance stock units— 5,575 6,550 5,422 
Weighted-average shares outstanding - diluted335,733 324,754 335,233 323,704 
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic$(0.06)$0.01 $0.30 $0.12 
Diluted$(0.06)$0.01 $0.29 $0.11 
The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Stock options
1,153 
(1)
347 
(2)
— 347 
(2)
Restricted stock units6,908 
(1)
— — — 
Performance stock units
6,571 
(1)
1,960 
(3)
— 1,960 
(3)
(1)Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.
(2)Excluded from the computation of diluted earnings per share of Class A common stock because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money).
(3)Excluded from the computation of diluted earnings per share of Class A common stock because the performance vesting conditions were not met during the period.
v3.26.3
Trade Accounts Receivable, Net
9 Months Ended
Sep. 30, 2026
Receivables [Abstract]  
Trade Accounts Receivable, Net Trade Accounts Receivable, Net
Trade accounts receivable, net was comprised of the following (in thousands):
September 30, 2026December 31, 2025
Gross accounts receivable$1,591,921 $1,740,324 
Allowance for credit losses(7,330)(3,003)
Contract charge-backs and sales volume allowances(535,505)(801,186)
Cash discount allowances(32,242)(40,992)
Subtotal(575,077)(845,181)
Trade accounts receivable, net$1,016,844 $895,143 
Concentration of Receivables
Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:
September 30, 2026December 31, 2025
Customer A39 %39 %
Customer B25 %23 %
Customer C24 %26 %
v3.26.3
Inventories
9 Months Ended
Sep. 30, 2026
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Raw materials$286,654 $227,353 
Work in process78,098 55,455 
Finished goods343,204 323,494 
Total inventories$707,956 $606,302 
v3.26.3
Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Deposits and advances$4,812 $4,437 
Prepaid insurance6,787 6,723 
Prepaid regulatory fees10,791 8,109 
Income and other tax receivables24,454 18,662 
Prepaid taxes14,482 17,068 
Accrued royalty income (1)
84,069 14,332 
Other current receivables9,440 5,295 
Chargebacks receivable7,815 5,972 
Other prepaid assets34,119 17,797 
Total prepaid expenses and other current assets$196,769 $98,395 
(1)The increase in accrued royalty income primarily reflects profit share income under the ALYMSYS® distribution agreement with Valorum Oncology, LLC, as described in Note 4. Alliance and Collaboration in the Company’s 2025 Annual Report on Form 10-K.
v3.26.3
Property, Plant, and Equipment, Net
9 Months Ended
Sep. 30, 2026
Property, Plant, and Equipment [Abstract]  
Property, Plant, and Equipment, Net Property, Plant, and Equipment, Net
Property, plant, and equipment, net was comprised of the following (in thousands):
September 30, 2026December 31, 2025
Land$20,559 $19,690 
Buildings234,777 234,599 
Leasehold improvements153,184 133,833 
Machinery and equipment546,778 473,076 
Furniture and fixtures17,574 16,170 
Vehicles2,282 2,018 
Computer equipment83,100 76,825 
Construction-in-progress147,773 92,909 
Total property, plant, and equipment1,206,027 1,049,120 
Less: Accumulated depreciation(633,393)(606,170)
Property, plant, and equipment, net$572,634 $442,950 
Depreciation expense for the three and nine months ended September 30, 2026 was $14.7 million and $40.8 million, respectively. Depreciation expense for the three and nine months ended September 30, 2025 was $14.5 million and $43.7 million, respectively.
During the three months ended September 30, 2026, the Company recorded a $13.8 million impairment charge related to certain equipment used in R&D activities as a result of a change in the expected future utilization of the assets. The impairment charge was recorded in R&D expense for the three and nine months ended September 30, 2026.
v3.26.3
Goodwill and Other Intangible Assets
9 Months Ended
Sep. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
The changes in goodwill by segment were as follows (in thousands):
Affordable MedicinesSpecialtyAvKARETotal
Balance as of December 31, 2024$161,659 $366,312 $69,465 $597,436 
Currency translation(1,966)— — (1,966)
Balance as of December 31, 2025159,693 366,312 69,465 595,470 
Goodwill acquired during the period179,478 — — 179,478 
Currency translation(2,475)— — (2,475)
Balance as of September 30, 2026$336,696 $366,312 $69,465 $772,473 
For the nine months ended September 30, 2026, goodwill acquired during the period was associated with the Kashiv Acquisition. Refer to Note 2. Acquisition for additional information.
Intangible assets as of September 30, 2026 and December 31, 2025 were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights5.8$1,768,413 $(1,071,688)$696,725 $1,519,694 $(977,819)$541,875 
Other intangible assets1.982,700 (77,270)5,430 82,700 (69,177)13,523 
Total1,851,113 (1,148,958)702,155 1,602,394 (1,046,996)555,398 
IPR&D
849,100 — 849,100 8,100 — 8,100 
Total intangible assets$2,700,213 $(1,148,958)$1,551,255 $1,610,494 $(1,046,996)$563,498 
In connection with the Kashiv Acquisition on August 10, 2026, the Company recognized $1,003.0 million of intangible assets at their preliminary acquisition-date fair values, consisting of $40.0 million of product rights and $963.0 million of IPR&D. Product rights are amortized to cost of goods sold over their estimated useful lives. Refer to Note 2. Acquisition for additional information regarding the preliminary purchase price allocation for the Kashiv Acquisition.
Amortization expense related to intangible assets for the three months ended September 30, 2026 and 2025 was $38.6 million and $39.6 million, respectively. Amortization expense related to intangible assets for the nine months ended September 30, 2026 and 2025 was $103.5 million and $130.6 million, respectively.
The following table presents future amortization expense for the next five years and thereafter, excluding $849.1 million of IPR&D intangible assets (in thousands):
Future Amortization
Remainder of 2026$45,026 
2027162,946 
2028117,468 
2029104,765 
2030105,989 
203192,587 
Thereafter73,374 
Total$702,155 
The Company reviews intangible assets with finite lives for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. Indefinite-lived intangible assets, including IPR&D intangible assets, are tested for impairment if impairment indicators arise and, at a minimum, annually. For the three and nine months ended September 30, 2026, intangible asset impairments were immaterial. For the three and nine months ended September 30, 2025, the Company recorded $22.8 million of intangible asset impairment charges in cost of goods sold. The charges primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the FDA regarding a supplemental new drug application.
v3.26.3
Other Assets
9 Months Ended
Sep. 30, 2026
Other Assets [Abstract]  
Other Assets Other Assets
Other assets were comprised of the following (in thousands): (1)
September 30, 2026December 31, 2025
Interest rate swap (2)
$33,775 $5,756 
Security deposits4,811 3,932 
Long-term deposits and prepaid expenses2,437 3,412 
Deferred revolving credit facility costs 4,331 5,197 
Long-term restricted cash8,680 2,068 
Equipment deposits48,068 34,332 
Other long-term assets 20,705 3,108 
Total other assets$122,807 $57,805 
(1)Certain prior period amounts have been reclassified to conform to the current period presentation. As of September 30, 2026, the Company separately presented equipment deposits within other assets to provide additional transparency regarding the nature of these balances. Such reclassifications had no impact on total other assets, total assets, results of operations, or cash flows.
(2)Refer to Note 16. Fair Value Measurements and Note 17. Financial Instruments for information about the Company’s interest rate swap.
v3.26.3
Accounts Payable and Accrued Expenses
9 Months Ended
Sep. 30, 2026
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Expenses Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Accounts payable$283,662 $254,671 
Accrued returns allowance (1)
191,513 179,471 
Accrued compensation90,790 79,886 
Accrued Medicaid and commercial rebates (1)
70,312 119,486 
Accrued royalties72,981 30,040 
Accrued professional fees20,904 14,514 
Accrued interest8,530 18,663 
Accrued other50,139 64,585 
Total accounts payable and accrued expenses$788,831 $761,316 
(1)Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2025 to September 30, 2026.
v3.26.3
Debt
9 Months Ended
Sep. 30, 2026
Debt Disclosure [Abstract]  
Debt Debt
Changes in the Company’s long-term debt since December 31, 2025 are disclosed below. Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information and definitions of certain terms used in this note.
The following is a summary of the Company’s long-term debt, including the current portion (in thousands):
September 30, 2026December 31, 2025
Term Loan Due 2032$2,434,263 $2,094,750 
Senior Notes Due 2032600,000 600,000 
Kashiv Rupee Term Loan Facility16,484 — 
Total debt3,050,747 2,694,750 
Less: debt issuance costs(111,313)(122,874)
Total debt, net of debt issuance costs2,939,434 2,571,876 
Less: current portion of long-term debt(23,933)(6,761)
Total long-term debt, net$2,915,501 $2,565,115 
Term Loans and Senior Notes
Repricing Amendments to Term Loan Credit Agreement
On February 2, 2026, the Company entered into a repricing amendment for the Term Loan Due 2032 (the “February 2026 Repricing Amendment”), which reduced the applicable interest rate margins on the Term Loan Due 2032 by 50 basis points to 3.00% per annum for term SOFR benchmark rate loans and 2.00% per annum for base rate loans. The stated maturity date of August 1, 2032 and aggregate principal did not change as a result of the amendment.
In connection with the February 2026 Repricing Amendment, the Company recognized a loss of $3.5 million for the nine months ended September 30, 2026, related to costs incurred as part of this transaction and the write‑off of unamortized debt issuance costs associated with the modified portion of the Term Loan Due 2032.
On August 3, 2026, the Company entered into another repricing amendment for the Term Loan Due 2032 (the “August 2026 Repricing Amendment”), which reduced the applicable interest rate margins on the Term Loan Due 2032 by 50 basis points to 2.50% per annum for term SOFR benchmark rate loans and 1.50% per annum for base rate loans. The stated maturity date of August 1, 2032 and aggregate principal did not change as a result of the amendment.
In connection with the August 2026 Repricing Amendment, the Company recognized a loss of $2.4 million for each of the three and nine months ended September 30, 2026, related to costs incurred as part of this transaction and the write‑off of unamortized debt issuance costs associated with the modified portion of the Term Loan Due 2032.
Acquisition Financing - Incremental Borrowing under Term Loan due 2032
On August 10, 2026, the Company entered into Amendment No. 4 to its Term Loan Credit Agreement. Pursuant to the amendment, the Company borrowed an additional $350.0 million under the Term Loan Due 2032 (the “Incremental Term Loans”) with substantially the same terms. The proceeds of the Incremental Term Loans were used to finance a portion of the cash consideration paid in connection with the Kashiv Acquisition. Beginning December 31, 2026, the Company will make quarterly principal payments of 0.25% of the aggregate outstanding balance of the Incremental Term Loans.
In connection with the incremental borrowings, the Company recognized a loss of $3.4 million for each of the three and nine months ended September 30, 2026, related to costs incurred as part of this transaction and the write‑off of unamortized debt issuance costs associated with the modified portion of the Term Loan Due 2032.
Kashiv Rupee Term Loan Facility
In connection with the Kashiv Acquisition, the Company assumed a rupee-denominated term loan facility (the “Kashiv Rupee Term Loan Facility”) with an outstanding principal balance of $16.6 million as of the acquisition date. The facility provided aggregate commitments of approximately $72.0 million, bore interest at a variable rate based on the benchmark rate plus an
applicable margin. The outstanding principal balance was $16.5 million as of September 30, 2026, which the Company repaid in full on October 1, 2026. The Kashiv Rupee Term Loan Facility was subsequently terminated.
2025 Revolving Credit Facility
During April and May 2026, the Company borrowed $100.0 million under the 2025 Revolving Credit Facility. On July 31, 2026, the Company borrowed an additional $30.0 million under the 2025 Revolving Credit Facility for working capital needs and other general corporate purposes. On August 5, 2026, the Company borrowed an additional $150.0 million under the 2025 Revolving Credit Facility in anticipation of funding a portion of the cash consideration payable in connection with the Kashiv Acquisition on August 10, 2026. Refer to Note 2. Acquisition for additional information about the Kashiv Acquisition. During August and September 2026, the Company repaid $100.0 million under the 2025 Revolving Credit Facility. As of September 30, 2026, the Company had $180.0 million outstanding on the 2025 Revolving Credit Facility. Subsequent to September 30, 2026, the Company repaid $50.0 million under the 2025 Revolving Credit Facility. Refer to Note 24. Subsequent Events for additional information.
The 2025 Revolving Credit Facility bears an interest rate equal to the alternate base rate (“ABR”) or SOFR, plus an applicable margin, in each case, subject to an ABR floor of 1.00% or a SOFR floor of 0.00%, as applicable. The applicable margin on borrowings under the 2025 Revolving Credit Facility ranges from 0.25% to 0.50% per annum for ABR loans and from 1.25% to 1.50% per annum for SOFR loans determined by the average historical excess availability.
v3.26.3
Other Long-Term Liabilities
9 Months Ended
Sep. 30, 2026
Other Liabilities Disclosure [Abstract]  
Other Long-Term Liabilities Other Long-Term Liabilities
Other long-term liabilities were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Long-term compensation$9,847 $11,354 
Deferred income (1)
26,598 7,324 
Other long-term liabilities1,352 13,585 
Total other long-term liabilities$37,797 $32,263 
(1)Deferred income was primarily from alliance and collaboration agreements with Orion Corporation, Zambon Biotech S.A., and Pfizer. Refer to Note 4. Alliance and Collaboration for additional information.
v3.26.3
Fair Value Measurements
9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets that were measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 (in thousands):
Fair Value Measurement Based on
September 30, 2026TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets
Interest rate swap (1)
$33,775 $— $33,775 $— 
Liabilities
Contingent consideration liability (2)
$383,000 $— $— $383,000 
December 31, 2025
Assets
Interest rate swap (1)
$5,756 $— $5,756 $— 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial
information and certain assumptions regarding past, present, and future market conditions. Refer to Note 17. Financial Instruments for information on the Company’s interest rate swap.
(2)The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of September 30, 2026, the contingent consideration liability associated with the Kashiv Acquisition of $383.0 million recorded in the Company’s consolidated balance sheet included $59.0 million in contingent consideration - related party - short term and $324.0 million in contingent consideration - related party - long-term. Refer to Note 2. Acquisition and Note 20. Related Party Transactions for additional information associated with the Kashiv Acquisition.
There were no transfers between levels in the fair value hierarchy during the nine months ended September 30, 2026.
Contingent Consideration
On August 10, 2026, the Company completed the Kashiv Acquisition, which provides for up to $350.0 million in undiscounted contingent payments based on the achievement of certain regulatory milestones in the United States and potential contingent royalties equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty periods during the twelve-year period following the closing of the Kashiv Acquisition.
There were no contingent payments made during the three and nine months ended September 30, 2026.
The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
Nine Months Ended September 30, 2026
Balance, December 31, 2025$— 
Addition due to the Kashiv Acquisition389,000 
Change in fair value during period(6,000)
Balance, September 30, 2026$383,000 
The fair value measurement of the contingent consideration liabilities was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, timing of achieving specified regulatory milestones and the estimated amount of future revenues and gross profits for the underlying products subject to contingent royalty payments. The contingent consideration liability is estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of the aforementioned inputs. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined.
The following table summarizes the significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration liabilities as of September 30, 2026:
Contingent Consideration Liability
Fair Value as of
September 30, 2026
(in thousands)
Valuation TechniqueUnobservable inputRange
Weighted Average (1)
Regulatory Milestones
$135,000Probability-weighted discounted cash flowDiscount rate5.8%–6.8%6.2%
Probability of payment20.2%–92.5%63.0%
Projected year of payment2027–20312029
Royalties
$248,000Monte Carlo SimulationDiscount rate5.4%–7.6%6.8%
Volatility25.0%–25.0%25.0%
Probability of payment (2)
20.2%–92.5%63.0%
Projected year of payment (3)
2027–20382032
(1)Unobservable inputs were weighted by the relative fair value of each product candidate acquired.
(2)Excludes three products that have all successfully launched as of September 30, 2026 and have a 100% probability of payment.
(3)Projected year of payment represents the estimated timing of royalty payments utilized in the Monte Carlo Simulation valuation model. Payments are expected to occur from 2027 through 2038, with approximately 50% of discounted expected payments occurring by 2032.
Assets and Liabilities Not Measured at Fair Value on a Recurring Basis
The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments. The carrying amount of the Kashiv Rupee Term Loan Facility approximated fair value as of September 30, 2026 due to its repayment on October 1, 2026. The carrying amount of the 2025 Revolving Credit Facility approximated fair value as of September 30, 2026 due to its variable interest rate, which reflects current market rates. The fair value measurement is classified within Level 2 of the fair value hierarchy.
The following is a summary of the Company’s indebtedness at fair value (in thousands):
September 30, 2026December 31, 2025
Term Loan Due 2032$2,446,434 $2,115,698 
Senior Notes Due 2032$601,500 $633,000 
The Term Loan Due 2032 and Senior Notes Due 2032 are each in the Level 2 category within the fair value hierarchy. The fair values were determined using market data for valuation.
Refer to Note 14. Debt in this Quarterly Report on Form 10-Q and Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about its indebtedness, including definitions of terms and additional information.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
There were no non-recurring fair value measurements during the nine months ended September 30, 2026 and 2025.
v3.26.3
Financial Instruments
9 Months Ended
Sep. 30, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates. Changes in fair value will be recognized in other comprehensive loss and reclassified to interest expense, net, in the period in which the hedged transaction affects earnings. During the three and nine months ended September 30, 2026, the Company reclassified a net loss (increase in interest expense) of $2.9 million and $8.7 million, respectively, from accumulated other comprehensive loss. As of September 30, 2026, a net gain of $21.9 million was recorded in accumulated other comprehensive loss associated with the impact of all interest rates swaps, with $7.6 million, net, expected to be reclassified within 12 months. Refer to Note 19. Stockholders’ Equity (Deficiency) in this Quarterly Report on Form 10-Q and Note 18. Financial Instruments in the Company’s 2025 Annual Report on Form 10-K for defined terms and additional information.
During the three and nine months ended September 30, 2025, the Company reclassified a net loss of $4.2 million (increase in interest expense, net) and net gain of $1.7 million (decrease in interest expense, net), respectively, from accumulated other comprehensive loss. As of December 31, 2025, $14.8 million in net losses were recorded in accumulated other comprehensive loss.
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
September 30, 2026December 31, 2025
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther Assets$33,775 Other Assets$5,756 
v3.26.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Commitments
Commercial Manufacturing, Collaboration, License, and Distribution Agreements
The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with
collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments and other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 4. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 20. Related Party Transactions for additional information.
Contingencies
Legal Proceedings
The Company’s legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies.
For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized.
For the three months ended September 30, 2026, charges related to legal matters, net were $6.5 million, primarily consisting of a charge related to government investigations of $8.0 million, partially offset by immaterial net credits related to several matters.
For the nine months ended September 30, 2026, charges related to legal matters, net were $15.2 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date, (ii) net charges associated with antitrust class action litigation of $7.5 million, and (iii) charges related to government investigations of $8.0 million. These charges were partially offset by immaterial net credits related to several other legal matters. For additional information regarding the Nationwide Opioids Settlement Agreement, antitrust class action litigation, and government investigations, refer to the section Other Litigation Regarding the Company’s Business below.
Liabilities for legal matters were comprised of the following (in thousands):
MatterSeptember 30, 2026December 31, 2025
Civil prescription opioid litigation (1)
$9,454 $42,271 
Government investigations8,000 — 
Antitrust class action litigation7,450 — 
Other
2,630 985 
Current portion of liabilities for legal matters$27,534 $43,256 
Civil prescription opioid litigation (Liabilities for legal matters - long term) (1)
$71,663 $71,819 
(1)As of September 30, 2026, the total current and long-term liabilities of $81.1 million for civil prescription opioid litigation were primarily comprised of an $80.6 million liability for the Nationwide Opioids Settlement Agreement effective January 23, 2026, as defined and described in the section Civil Prescription Opioid Litigation below. Of the $80.6 million accrued for this settlement agreement, $79.7 million was for cash payments and $0.9 million was for the supply of naloxone nasal spray.
As of September 30, 2026, the remaining cash payments under the Nationwide Opioids Settlement Agreement, due on March 1 of each year, were as follows (in thousands):
Amount Due
2027$12,670 
202812,389 
202912,389 
203012,389 
2031 (1)
11,939 
2032 to 2034 (1)
35,816 
Total settlement payments$97,592 
Less: imputed interest at a rate of 5.5%
(17,917)
Total $79,675 
(1)Amounts due in each of 2031 through 2034 include approximately $10.4 million of cash conversion payments associated with certain settling parties’ elections to receive cash in lieu of naloxone nasal spray under the Nationwide Opioids Settlement Agreement ($41.4 million in the aggregate).
The discount-related imputed interest will be amortized to interest expense over the life of the liability using the effective interest method. Interest expense associated with the Nationwide Opioids Settlement Agreement for the three and nine months ended September 30, 2026 was immaterial.
Refer to Note 19. Commitments and Contingencies in the Company’s Annual Report on Form 10-K for a general discussion of Medicaid Reimbursement and Price Reporting Matters and Patent Litigation.
Other Litigation Related to the Company’s Business
United States Department of Justice Investigations
On May 15, 2023, Amneal Pharmaceuticals LLC (“Amneal”) received a Civil Investigative Demand (“CID”) from the Civil Division of the United States Department of Justice (the “Civil Division”) requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. In October 2024, the Company received supplemental CIDs seeking additional information related to the same subject matter. The Company is continuing to cooperate with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation.
In Re Generic Pharmaceuticals Pricing Antitrust Litigation
Beginning in March 2016, purchasers of generic drugs filed multiple putative antitrust class action complaints against a substantial number of generic pharmaceutical manufacturers, including the Company, alleging an illegal conspiracy to fix prices, rig bids, and allocate markets and customers. They seek monetary damages and equitable relief, including disgorgement and restitution. Most of these lawsuits were consolidated in the United States District Court for the Eastern District of Pennsylvania (See In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 (E.D. Pa.)). Some purchasers
filed similar lawsuits in state courts in Pennsylvania, Connecticut, and New York. The Company has filed several motions to dismiss these cases, and some of those motions remain pending.
In 2019 and 2020, Attorneys General of 43 States and the Commonwealth of Puerto Rico named the Company in two complaints alleging a similar conspiracy and seeking similar relief. These cases are pending in the District of Connecticut. See Connecticut, et al. v. Teva Pharmaceuticals USA, Inc., et al., 3:19-cv-00710-MPS and Connecticut, et al. v. Sandoz, Inc. et al., 3:20-cv-00802-MPS.
In Connecticut, et al. v. Sandoz, Inc. et al., on April 15, 2026, the Court granted the Company’s individual motion for summary judgment with respect to the states’ claim that the Company participated in an overreaching conspiracy involving more than 80 drugs and denied the Company’s motion with respect to an alleged conspiracy involving only one drug, phenytoin.
The multi-district litigation (“MDL”) court selected Humana Inc. v. Actavis Elizabeth, LLC et al., No. 2:18-cv-03299-CMR (“Humana I”), which names Impax Laboratories, LLC (“Impax”) as a defendant, as a bellwether and set a trial for September 2026. On March 26, 2026, Impax filed an individual motion for summary judgment and four joint motions for summary judgment in Humana I. Those summary judgment motions were fully briefed on May 22, 2026 and remain pending. On August 4, 2026, the Court denied Defendants’ joint motion for partial summary judgment on statute of limitations grounds as to certain federal claims, and on September 28, 2026, it denied the motion as to certain state-law claims. Defendants’ joint summary judgment motion on damages was denied on August 19, 2026, and defendants’ joint summary judgment motion on overarching conspiracy was denied on August 26, 2026. On September 14, 2026, Defendants’ joint summary judgment motion on state-law claims was granted in part and denied in part. Impax’s individual motion for summary judgment remains pending. On September 2, 2026, the Court stayed proceedings and continued the trial date in light of a dispute regarding a possible conflict of interest involving one of the appointed special masters. The other MDL cases and the state court cases are in various stages of pleading and discovery. No other trials involving the Company have been set.
Civil Prescription Opioid Litigation
As a result of the Court’s Stipulation and Order dated February 26, 2026, pursuant to the settlement of the political subdivision cases in MDL 2804, the state and federal cases against the Company relating to the sale of prescription opioid pain relievers have been reduced from over 800 cases to less than 70 cases, comprised of 24 cases in MDL 2804 and other federal courts, and 42 state court cases. Plaintiffs in the remaining cases are political subdivisions (pending dismissal), schools, hospitals, pension funds, third-party payors, and individuals. Nearly all federal court cases are consolidated for pre-trial proceedings in Case No. 17-mdl-2804 (N.D. Ohio). There are no firm trial dates in the state-court cases.
The New York, Alaska, and Maryland Attorneys General have withdrawn their subpoenas seeking information regarding the Company’s business concerning opioid-containing products.
In 2023, the Company reached settlements with the New Mexico Attorney General and West Virginia political subdivisions and a settlement with a group of private hospitals in Alabama. On March 30, 2026, the court in Alabama dismissed the hospital cases against the Company pursuant to the settlement agreement.
In late April 2024, the Company reached a nationwide settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases filed and that might have been filed by state Attorneys General, political subdivisions and Native American tribes. In September 2025, the Native American tribal participation reached a sufficient percentage to effectuate the tribal settlement. On January 23, 2026, the Company determined that it will make effective its nationwide agreement to settle a substantial majority of the opioids-related claims brought against the Company by various states and subdivisions (the “Nationwide Opioids Settlement Agreement”), having previously secured sufficient participation by those states and subdivisions, including all eligible state and territorial Attorneys General and all subdivisions that previously sued the Company. The Nationwide Opioids Settlement Agreement became effective on January 29, 2026, and the Company made its first installment payment of $23.8 million to the settlement administrator on that date. An additional installment payment of $12.1 million was made on February 26, 2026. The settlement is payable through 2034. Under the settlement, the Company agreed to pay up to $92.5 million in cash and provide $177.4 million (valued at $125/twin pack) in naloxone nasal spray to help treat opioid overdoses. In lieu of receiving product, the settling parties can opt to receive 25% of the naloxone nasal spray’s value (up to $44.4 million) in cash during the last four years of the ten-year payment term, which could increase the total amount of cash the Company would pay up to $136.9 million. In March 2026, five states elected to receive $11.6 million in free naloxone nasal spray with the remaining states electing to receive the 25% cash conversion. As a result, and assuming other states do not subsequently decide to instead receive settlement product, Amneal will pay $41.4 million in cash in equal distributions of $10.4 million from 2031 to 2034. Including these cash conversion payments, the Company’s total cash payments under the Nationwide Opioids Settlement Agreement will be $133.5 million.
Refer to the section Legal Proceedings above for amounts charged to the statements of operations for the three and nine months ended September 30, 2026 and liabilities as of September 30, 2026 and December 31, 2025, associated with civil prescription opioid litigation. For the remaining cases not covered by the Nationwide Opioids Settlement Agreement, primarily brought by other hospitals, schools and individuals, the Company did not record a liability as of September 30, 2026 and December 31, 2025 because it concluded that a loss was not probable and estimable.
During July 2025, the Company deposited an aggregate of $24.2 million into dedicated accounts as a step in the process to finalize a definitive settlement agreement. These deposits, which were classified as restricted cash in the Company’s consolidated balance sheet as of December 31, 2025, remained the property of the Company until a definitive settlement agreement was reached and the funds were used to make the first installment payment under the Nationwide Opioids Settlement Agreement. Accordingly, no related restricted cash balance remained as of September 30, 2026.
United States Department of Justice / Drug Enforcement Administration Subpoenas
On July 7, 2017, Amneal Pharmaceuticals of New York, LLC received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company has been cooperating with the USAO in responding to the subpoenas. The Company entered into tolling agreements with respect to potential criminal charges through May 15, 2026. The Company entered into tolling agreements with respect to potential civil claims through November 15, 2024. It is not possible to determine the exact outcome of these investigations.
On December 21, 2025, the Company received an administrative subpoena from the DEA relating to sales of controlled substances to Dixon Shane, LLC d/b/a R&S Northeast LLC (“R&S Northeast”), an indirect subsidiary that distributes generic pharmaceuticals manufactured by Amneal and others. On the same date, R&S Northeast received an administrative subpoena from the DEA relating to various policies and procedures relating to controlled substances and controlled substance order monitoring, as well as other information relating to current and former customers. The Company and R&S Northeast have been cooperating with DEA and responding to the subpoenas. It is not possible to determine the exact outcome of this investigation.
Ranitidine Litigation
The Company was named, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products in a federal MDL (In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), Southern District of Florida). Plaintiffs alleged defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in ranitidine products and the alleged associated risk of cancer. The MDL court’s dismissal of claims by all plaintiffs against the Company and other generic drug manufacturers on preemption grounds is on appeal in the 11th Circuit. Plaintiffs filed their merits brief on April 10, 2024. The generic drug manufacturers, including the Company, filed their briefs on July 25, 2024. Plaintiffs’ reply brief was filed November 8, 2024. The briefing also addresses the MDL court’s December 6, 2022 exclusion of plaintiff’s general causation experts. The 11th Circuit heard oral argument on October 10, 2025. The timeline for the 11th Circuit Court of Appeals’ rulings is uncertain.
The Company has also been named in state court cases in four states. The Company filed motions to dismiss those cases. On August 17, 2023, the judge in the consolidated Illinois state court cases granted the motion to dismiss all such cases in which the Company had been named, holding all claims preempted. The Company has reached an agreement, which is not material, to settle the 95 cases pending against it in California state court. The process for completing the settlement, which the Company does not expect to be material, is in progress. There are no trial dates involving the Company in any of the state court cases.
Metformin Litigation
Beginning in 2020, Amneal was named as a defendant in several putative class action lawsuits filed and consolidated in the United States District Court for the District of New Jersey, seeking compensation for economic loss allegedly incurred in connection with their purchase of generic metformin allegedly contaminated with NDMA. See In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH) (“In re Metformin”). On January 30, 2026, the Court issued an Order granting in part and denying in part Defendants’ motion to dismiss the Fourth Amended Complaint. Discovery is ongoing.
On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin (See Davis v. Camber Pharmaceuticals, Inc., et al.,
C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation MDL for pretrial proceedings.
UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc.
On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against multiple manufacturers, including the Company, alleging an illegal conspiracy to restrict output of generic COLCRYS®. See UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma. U.S.A., Inc. et al, No. 1:23-cv-10030 (S.D.N.Y.). On February 28, 2024, Takeda Pharmaceuticals U.S.A., Inc. filed a motion to transfer the case to the United States District Court for the Eastern District of Pennsylvania. The case was transferred on April 28, 2026. See UFCW Local 1500 Welfare Fund et al. v. Takeda Pharma U.S.A., Inc., et al. No. 2:26-cv-3122 (E.D. Pa.). Defendants’ motion to dismiss the case was filed on June 9, 2026. That motion is fully briefed and is pending before the Court.
Indian Tax Authority Matters
Amneal Pharmaceuticals Pvt. Ltd. and RAKS Pharmaceuticals Pvt. Ltd., which are subsidiaries of the Company, are currently involved in litigations with Indian tax authorities concerning Central Excise Tax, Service Tax, Goods & Services Tax, and Value Added Tax for various periods of time between 2014 and 2017. These subsidiaries have contested certain of these assessments, which are at various stages of the administrative process. The Company strongly believes its Indian subsidiaries have meritorious defenses in the matter.
Guaifenesin Litigation
On June 27, 2025, CVS Pharmacy, Inc. (“CVS”), which Amneal is defending, was named as a defendant in a putative consumer class action lawsuit in the United States District Court for the Northern District of Illinois, alleging that generic guaifenesin products sold by CVS (and manufactured by Amneal) contain benzene through the use of carbomer, an inactive ingredient. See Hatfield v. CVS Health Corporation, No. 1:25-cv-7248 (N.D. Ill.). On September 3, 2026, the Court granted CVS’s motion to dismiss without prejudice. Plaintiff filed a notice of voluntary dismissal with prejudice on October 8, 2026, and the case has been terminated.
Amneal Pharmaceuticals LLC et al. v. Sandoz Inc.
On November 25, 2024, the Company and Impax received the first of five notice letters from Sandoz Inc. (“Sandoz”) stating that Sandoz had filed an ANDA with the FDA seeking approval to market generic versions of CREXONT®, an extended-release oral capsule formulation of carbidopa and levodopa for the treatment of Parkinson’s disease. The notice letters included a Paragraph IV certifications alleging that certain patents covering CREXONT® are invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of Sandoz’s generic product.
In response to these notice letters, on January 7, 2025, the Company and Impax filed a first patent infringement lawsuit against Sandoz in the U.S. District Court for the District of New Jersey, Case No. 3:25-cv-00181-GC-TJB. The filing of this lawsuit triggered a 30-month stay of FDA approval of the Sandoz ANDA from the date of receipt of the notice letter. CREXONT® is also subject to a regulatory exclusivity until August 7, 2027.
On June 20, 2025, the Company and Impax filed another patent infringement lawsuit against Sandoz in the U.S. District Court for the District of New Jersey, captioned Amneal Pharmaceuticals LLC et al. v. Sandoz Inc., D.N.J. 2:25-11981-GC-TJB. On November 12, 2025, the Company and Impax filed another patent infringement lawsuit against Sandoz in the U.S. District Court for the District of New Jersey, captioned Amneal Pharmaceuticals LLC et al. v. Sandoz Inc., D.N.J. 2:25-17384-GC-TJB.
On October 9, 2026, the Company, Impax, and Sandoz entered into a settlement and license agreement to resolve their disputes. Under the terms of that agreement, the Company and Impax granted Sandoz a license to begin selling generic versions of CREXONT® on December 21, 2037, or earlier under certain circumstances. On November 3, 2026, the three above lawsuits were dismissed without prejudice.
Amneal Pharmaceuticals LLC et al. v. Alembic Pharmaceuticals Ltd.
On May 26, 2026, the Company and Impax received a notice letter from Alembic Pharmaceuticals Ltd (“Alembic”) stating that it had filed an ANDA with the FDA seeking approval to market generic versions of CREXONT®, an extended-release oral capsule formulation of carbidopa and levodopa for the treatment of Parkinson’s disease. The notice letter included Paragraph IV
certifications alleging that certain patents covering CREXONT® are invalid, unenforceable or will not be infringed by the manufacture, use or sale of Sandoz’s generic product.
In response to the notice letter, on July 2, 2026, the Company and Impax filed an infringement lawsuit against Alembic in the U.S. District Court for the District of Delaware, Case No. 26-cv-00798. This lawsuit is currently in the initial pleadings and discovery stage. The filing of this lawsuit triggered a 30-month stay of FDA approval of the Alembic ANDA from the date of receipt of the notice letter. CREXONT® is also subject to a regulatory exclusivity until August 7, 2027.
Carickhoff v. Amneal Pharmaceuticals, Inc., et al.
On May 7, 2025, the Liquidating Trustee on Behalf of the Vyera Liquidating Trust Established Under the Subchapter V Plan of Reorganization of debtors Vyera Pharmaceuticals, LLC and Phoenixus AG filed an adversary proceeding in the United States Bankruptcy Court for the District of Delaware against the Company and Impax, seeking to recover approximately $55.4 million in allegedly fraudulent transfers made by the debtors to Impax to purchase the drug Daraprim in 2015. (See Carickhoff v. Amneal Pharmaceuticals, Inc, et al., Adv. Pro. No. 25-50903-JKS (Bankr. D. Del.)). Defendants filed a motion to dismiss the complaint on September 9, 2025. That motion is fully briefed and is pending before the Court.
Shareholder Litigation Related to Agreement to Acquire Kashiv Biosciences, LLC
Two complaints were filed by purported shareholders of the Company against the Company and certain directors and officers of the Company related to the Company’s agreement to acquire Kashiv Biosciences, LLC. The complaints were captioned: (i) Johnson v. Amneal Pharmaceuticals, Inc., et al., No. 654043/2026 (N.Y. Sup. Ct. July 8, 2026); and (ii) Kent v. Amneal Pharmaceuticals, Inc., et al., No. 654067/2026 (N.Y. Sup. Ct. July 9, 2026) (collectively, the “Complaints”). The Complaints sought to enjoin the defendants from proceeding with the Kashiv Acquisition unless the defendants disclosed certain purportedly material information alleged to have been omitted from the definitive proxy statement related to the solicitation of shareholder approval of the transaction and sought rescission of the Kashiv Acquisition and/or damages if the Kashiv Acquisition was consummated. Plaintiffs did not serve or otherwise pursue the Complaints, and the Kashiv Acquisition closed on August 10, 2026. Refer to Note 2. Acquisition for information about the Kashiv Acquisition.
Value Drug Company v. Amneal Pharmaceuticals, Inc.
On July 27, 2026, Value Drug Company filed a purported class action lawsuit on behalf of itself and other direct purchasers of RYTARY® or generic versions of RYTARY® in the Northern District of California alleging that Amneal and Impax illegally conspired with generic manufacturers Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited to suppress price competition for RYTARY®. See Value Drug Company v. Amneal Pharmaceuticals LLC et al, No. 5:26-cv-7780 (N.D. Cal.). Value Drug Company filed an amended complaint on September 17, 2026. Defendants’ motion to dismiss the amended complaint is due on November 18, 2026.
v3.26.3
Stockholders’ Equity (Deficiency)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders’ Equity (Deficiency) Stockholders’ Equity (Deficiency)
Accumulated Other Comprehensive Loss
Changes in accumulated other comprehensive loss by component were as follows (in thousands):
Foreign
currency
translation
adjustments
Unrealized (loss) gain on cash
flow hedge, net
of tax
OtherAccumulated
other
comprehensive loss
December 31, 2025$(90,545)$(14,844)$(5,340)$(110,729)
Other comprehensive (loss) gain before reclassification(13,332)28,019 4,228 18,915 
Reclassification of cash flow hedge to earnings, net of tax of $0
— 8,730 — 8,730 
September 30, 2026$(103,877)$21,905 $(1,112)$(83,084)
December 31, 2024$(71,860)$6,350 $— $(65,510)
Other comprehensive loss before reclassification(15,648)(23,011)— (38,659)
Reclassification of cash flow hedge to earnings, net of tax of $0
— (1,714)— (1,714)
September 30, 2025$(87,508)$(18,375)$— $(105,883)
Rondo Redeemable Non-Controlling Interests
Beginning January 1, 2026, the holders of the Rondo Class B Units, as defined and discussed in Note 20. Stockholders’ (Deficiency) Equity to the Company’s 2025 Annual Report on Form 10-K, have a put right to require the Company to purchase their units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization, subject to the satisfaction of certain financial targets and other conditions. 
On September 15, 2026, the Company entered into an equity purchase agreement to acquire a portion of the outstanding Rondo Class B Units for cash consideration of $19.8 million. Based on the terms of the agreement, the Company concluded that redemption of the related redeemable non-controlling interest was probable and, as of September 30, 2026, accreted the non-controlling interest to its redemption value, resulting in $14.2 million of accretion during the three and nine months ended September 30, 2026. The Company evaluated the remaining outstanding Rondo Class B Units and concluded that redemption was not probable; accordingly, no additional accretion was recognized. The transaction closed on October 1, 2026 and increased the Company's ownership interest in Rondo from approximately 65.1% to 66.4%.
Acquisition of Non-Controlling Interests in Amneal Complex Products Research LLC
The Company acquired a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), now known as Amneal Complex Products Research LLC (“CPR”), on April 2, 2021. On May 31, 2026, the Company acquired the remaining 2% non-controlling interests in CPR from the sellers of KSP, who are related parties, for cash consideration of $0.4 million. The carrying value of the acquired non-controlling interest was $0.6 million. Following the acquisition, CPR became a wholly owned subsidiary of the Company.
Shares Issued in Connection with the Kashiv Acquisition
On August 10, 2026, the Company issued 28.9 million shares of its Class A common stock to the sellers of Kashiv as the equity portion of the preliminary purchase consideration for the Kashiv Acquisition. Refer to Note 2. Acquisition for additional information about the acquisition and preliminary purchase consideration.
v3.26.3
Related Party Transactions
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. Except as disclosed below, as of and for the three and nine months ended September 30, 2026, there were no material changes to our related party agreements or relationships as defined and described in Note 22. Related Party Transactions and Note 20. Stockholders’ (Deficiency) Equity in the Company’s 2025 Annual Report on Form 10-K.
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations2026202520262025
Kashiv (1)
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$1,654 $3,353 $7,533 $11,148 
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$407 $3,602 $5,042 $9,218 
Generic development supply agreement - recognition of deferred incomeResearch and development$(163)$— $(163)$— 
Development and commercialization agreement - OmalizumabResearch and development$— $22,500 $— $22,500 
Generic development supply agreement - research and development materialResearch and development$— $(502)$— $(502)
Storage agreementResearch and development$— $(71)$— $(189)
Development and commercialization agreement - Pegfilgrastim Auto Injector - milestoneResearch and development$— $— $500 $3,000 
Development and commercialization agreement - CarfilzomibResearch and development$— $— $— $2,000 
Parking space leaseResearch and development$— $— $— $25 
Generic development supply agreement - development activity deferred incomeAccounts payable and
accrued expenses
$— $— $— $(99)
Other Related Parties
Members - tax receivable agreementIncrease (decrease) in tax receivable agreement liability$12,992 $(20,808)$13,098 $(5,701)
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,067 $4,634 $16,218 $15,973 
Sellers of Kashiv - change in fair value of contingent consideration (2)
Change in fair value of contingent consideration$(6,000)$— $(6,000)$— 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$861 $185 $2,545 $2,512 
Kanan, LLC - operating leaseInventory and cost of goods sold$654 $592 $1,938 $1,776 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$405 $333 $1,143 $987 
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expenseCost of goods sold$314 $— $1,178 $— 
Direct Customer Solutions, LLC - warehousing/logistics/distribution servicesSelling, general and administrative$166 $— $295 $— 
Twenty NEA, LLC - operating lease (3)
Cost of goods sold$104 $— $104 $— 
Tracy Properties LLC - operating leaseSelling, general and administrative$81 $152 $248 $478 
Avtar Investments, LLC - consulting servicesResearch and development$60 $60 $180 $180 
AvPROP, LLC - operating leaseSelling, general and administrative$48 $46 $130 $150 
Avtar Investments, LLC - office rental space (3)
Selling, general and administrative$34 $— $34 $— 
Land purchase from family members of the Co-Chief Executive OfficersProperty, plant and equipment$— $— $— $11,289 
Ellodi Pharmaceuticals, L.P. - securities purchase and license and collaboration agreementsResearch and development$— $338 $— $6,046 
R&S Solutions - equipment purchaseProperty, plant and equipment$— $47 $— $207 
Alkermes PlcInventory and cost of goods sold$— $3 $— $67 
(1)Amounts relate to agreements previously between Amneal and Kashiv that were acquired in the Kashiv Acquisition and, following the closing of the transaction on August 10, 2026, became transactions among Amneal’s consolidated subsidiaries. Accordingly, the amounts presented for the three and nine months ended September 30, 2026 reflect activity only through August 10, 2026.
(2)Represents changes in the fair value of contingent consideration liabilities payable to the sellers of Kashiv pursuant to the Purchase Agreement.
(3)These agreements were acquired in the Kashiv Acquisition and are included in the Company’s related party disclosures for the three and nine months ended September 30, 2026 because the counterparties meet the definition of related parties. The amounts presented reflect activity from the acquisition date through September 30, 2026.
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
September 30, 2026December 31, 2025
Preliminary working capital adjustment - sellers of Kashiv$1,814 $— 
AzaTech Pharma LLC62 56 
Kashiv - various agreements— 413 
Apace Packaging, LLC - packaging agreement— 1 
Related party receivables - short term $1,876 $470 
Members - tax receivable agreement$16,323 $38,832 
Apace Packaging, LLC - packaging agreement1,640 1,353 
AzaTech Pharma LLC - supply agreement505 254 
PharmaSophia, LLC - license and commercialization agreement314 — 
Avtar Investments LLC - consulting services74 40 
Direct Customer Solutions, LLC57 — 
Kashiv - various agreements— 14,980 
Tracy Properties LLC— 26 
Related party payables - short term $18,913 $55,485 
Members - tax receivable agreement$15,432 $18,656 
Land purchase from family members of the Co-Chief Executive Officers446 476 
Related party payables - long term $15,878 $19,132 
Master Logistics Services Agreement with DCS
On February 24, 2026, the Company entered into a master logistics services agreement with Direct Customer Solutions, LLC (“DCS”), a third-party logistics provider specializing in the life sciences industry. Under the agreement, DCS will provide logistics services on behalf of the Company, including transportation, warehousing, and end-to-end supply chain management for certain products. A member of Company management beneficially owns outstanding equity securities of DCS.
Pursuant to the agreement, the Company paid DCS an immaterial one-time setup fee, a per-unit distribution fee, and a minimum monthly maintenance fee. For the three and nine months ended September 30, 2026, the Company recorded selling, general and administrative expense of $0.2 million and $0.3 million, respectively, and a short term payable of $0.1 million as of September 30, 2026, related to these services.
License and Commercialization Agreement with PharmaSophia, LLC
PharmaSophia, LLC (“PharmaSophia”) is a joint venture formed by Nava Pharma, LLC (“Nava”) and Oakwood Laboratories, LLC for the purpose of developing certain products. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, these executive officers also serve on the Board of Managers of PharmaSophia.
In October 2022, PharmaSophia and Amneal entered into an exclusive license and commercialization agreement (the “PharmaSophia Agreement”) to develop, manufacture, and sell one injectable product (risperidone). PharmaSophia receives a 50% profit share for all sales of product made by Amneal under the PharmaSophia Agreement. For the three and nine months ended September 30, 2026, the Company recorded royalty expense of $0.3 million and $1.2 million, respectively, related to this agreement. Amounts payable to PharmaSophia under the agreement were $0.3 million as of September 30, 2026.
Agreement to Acquire Complex Products Research, LLC Non-Controlling Interest
On May 31, 2026, the Company acquired the remaining 2% non-controlling interests in CPR from the sellers of KSP, which are related parties, for cash consideration of $0.4 million. Refer to Note 19. Stockholders’ Equity (Deficiency) for additional information.
Acquisition of Kashiv Biosciences, LLC
Pre-Acquisition Related Party Transactions
On August 10, 2026, the Company completed the Kashiv Acquisition. Prior to closing of the transaction, Kashiv and the Company were related parties. Following the closing, agreements previously between Amneal and Kashiv became intercompany arrangements between Amneal’s consolidated subsidiaries. Accordingly, the amounts presented for the three and nine months ended September 30, 2026 reflect activity only through August 10, 2026. Amounts due to and from Kashiv prior to closing were settled as part of the transaction.
Certain executive officers and a member of the Company’s Board of Directors beneficially owned, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, equity interests in Kashiv and served on the Board of Managers of Kashiv prior to the acquisition date.
For additional information about related party transactions between the Company and Kashiv, refer to Note 22. Related Party Transactions in the Company’s 2025 Annual Report on Form 10-K.
Contingent Consideration and Purchase Price Adjustments
The sellers of Kashiv are eligible to receive contingent milestone and royalty payments pursuant to the Purchase Agreement. Certain sellers remain related parties of the Company, including certain executive officers and a member of the Company’s Board of Directors. As of September 30, 2026, the Company had a receivable of $1.8 million from the sellers for post-closing purchase price adjustments, presented as “Preliminary working capital adjustment - sellers of Kashiv” within related party receivables - short term in the table above. The Company also had a contingent consideration liability of $383.0 million, including $59.0 million classified as current liabilities and $324.0 million classified as long-term liabilities in the Company’s consolidated balance sheets.
Refer to Note 2. Acquisition and Note 16. Fair Value Measurements for additional information regarding the Kashiv Acquisition, including the purchase consideration, contingent consideration arrangements and preliminary purchase price allocation.
Acquired contracts with related parties
Certain agreements acquired as part of the Kashiv Acquisition are with counterparties that qualify as related parties of the Company. These agreements include an operating lease with Twenty NEA, LLC (“Twenty NEA”) under which Kashiv leases a research, development and manufacturing facility and a short-term lease arrangement with Avtar Investments, LLC (“Avtar”) to lease office space, both of which are located in the United States.
Certain executive officers and a member of the Amneal Group beneficially own, directly or through certain revocable or irrevocable trusts established for the benefit of their immediate families, equity interests in Twenty NEA. As described in Note 22. Related Party Transactions in the Company’s 2025 Annual Report on Form 10-K, certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, equity securities in Avtar, a private investment firm.
v3.26.3
Segment Information
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has three reportable segments: Affordable Medicines, Specialty, and AvKARE. Beginning in the third quarter of 2026, the results of Kashiv are included within the Affordable Medicines segment for segment reporting purposes. Refer to Note 2. Acquisition for additional information.
Chief Operating Decision Makers
The Company’s Co-Chief Executive Officers are the Company’s chief operating decision makers (“CODMs”). The CODMs evaluate the financial performance of the Company based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the
Company’s CODMs. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, acquisition costs, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s CODMs.
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended September 30, 2026
Affordable Medicines (1)
SpecialtyAvKARECorporate
and Other
Total
Company
Net revenue$547,109 $150,262 $165,313 $— $862,684 
Cost of goods sold352,331 46,212 130,023 — 528,566 
Gross profit194,778 104,050 35,290 — 334,118 
Selling, general and administrative32,097 36,969 A17,919 52,660 139,645 
Research and development63,418 B4,956 B— — 68,374 
Intellectual property legal development expenses2,138 55 — — 2,193 
Acquisition and integration costs— — — 22,320 22,320 
Restructuring and other charges891 — — 45 936 
Change in fair value of contingent consideration(6,000)— — — (6,000)
Charges for property losses and associated expenses5,334 35 — — 5,369 
Charges (credit) related to legal matters, net
5,500 1,000 — (3)6,497 
Other operating income(631)— — — (631)
Operating income (loss)$92,031 $61,035 $17,371 $(75,022)$95,415 
Nine Months Ended September 30, 2026
Affordable Medicines (1)
SpecialtyAvKARECorporate
and Other
Total
Company
Net revenue$1,460,259 $432,822 $488,319 $— $2,381,400 
Cost of goods sold867,459 137,497 387,705 — 1,392,661 
Gross profit592,800 295,325 100,614 — 988,739 
Selling, general and administrative115,782 111,755 A51,512 148,178 427,227 
Research and development129,727 B16,047 B— — 145,774 
Intellectual property legal development expenses5,633 189 — — 5,822 
Acquisition and integration costs— — — 35,073 35,073 
Restructuring and other charges891 347 — 902 2,140 
Change in fair value of contingent consideration(6,000)— — — (6,000)
Charges for property losses and associated expenses5,334 35 — — 5,369 
Charges (credit) related to legal matters, net
14,251 1,000 — (3)15,248 
Other operating income(8,870)— — — (8,870)
Operating income (loss)$336,052 $165,952 $49,102 $(184,150)$366,956 
Three Months Ended September 30, 2025
Affordable Medicines (1)
SpecialtyAvKARE Corporate
and Other
Total
Company
Net revenue$460,741 $125,240 $198,532 $— $784,513 
Cost of goods sold280,463 73,808 156,268 — 510,539 
Gross profit180,278 51,432 42,264 — 273,974 
Selling, general and administrative37,173 33,580 A15,234 51,828 137,815 
Research and development55,124 B8,228 B— — 63,352 
Intellectual property legal development expenses2,378 59 — — 2,437 
Restructuring and other charges90 — — 53 143 
Other operating income(117)— — — (117)
Operating income (loss)$85,630 $9,565 $27,030 $(51,881)$70,344 
Nine Months Ended September 30, 2025
Affordable Medicines (1)
SpecialtyAvKARE Corporate
and Other
Total
Company
Net revenue$1,308,874 $361,580 $533,987 $— $2,204,441 
Cost of goods sold775,742 182,686 429,895 — 1,388,323 
Gross profit533,132 178,894 104,092 — 816,118 
Selling, general and administrative105,114 94,872 A46,007 134,376 380,369 
Research and development128,003 B23,353 B— — 151,356 
Intellectual property legal development expenses6,069 152 — — 6,221 
Restructuring and other charges773 471 — 494 1,738 
Credit related to legal matters, net(390)— — — (390)
Other operating income(5,239)— — — (5,239)
Operating income (loss)$298,802 $60,046 $58,085 $(134,870)$282,063 
(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in Affordable Medicines.
Significant Expense Categories Provided to the Chief Operating Decision Makers
Selling, General and Administrative Expenses - Specialty Segment
A.The CODMs review certain selling, general and administrative expenses (“SG&A”) for the Specialty segment and, separately, on a departmental basis. The CODMs review SG&A for the Affordable Medicines and AvKARE segments in total. SG&A for the Specialty segment was comprised of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Employee compensation and benefits$13,315 $10,972 $38,188 $32,635 
Product marketing10,231 11,273 32,039 29,168 
Commercial operations and salesforce12,951 9,769 38,326 29,347 
Other (1)
472 1,566 3,202 3,722 
Total$36,969 $33,580 $111,755 $94,872 
(1)Other includes professional fees and other expenses not presented to the CODMs.
Research and Development Expenses - Affordable Medicines and Specialty Segments
B.Research and development expenses for the Affordable Medicines and Specialty segments were comprised of the following (in thousands):
Three Months Ended September 30,
20262025
Affordable MedicinesSpecialtyAffordable MedicinesSpecialty
Employee compensation and benefits$12,343 $1,658 $13,905 $1,089 
Materials and supplies6,944 842 6,230 1,358 
Product development and studies (1)
127 1,715 673 2,823 
In-licensing and upfront milestones— — 22,500 — 
Facilities costs1,654 45 1,755 409 
Regulatory fees704 — 2,317 — 
Kashiv R&D expenses (2)
19,421 — — — 
Other (3)
22,225 696 7,744 2,549 
Total$63,418 $4,956 $55,124 $8,228 
Nine Months Ended September 30,
20262025
Affordable MedicinesSpecialtyAffordable MedicinesSpecialty
Employee compensation and benefits$37,382 $4,303 $42,139 $3,908 
Materials and supplies24,555 1,924 22,865 2,011 
Product development and studies (1)
963 7,108 1,360 7,513 
In-licensing and upfront milestones4,000 — 29,100 3,000 
Facilities costs4,623 110 5,182 1,894 
Regulatory fees4,432 — 4,834 — 
Kashiv R&D expenses (2)
19,421 — — — 
Other (3)
34,351 2,602 22,523 5,027 
Total$129,727 $16,047 $128,003 $23,353 
(1)For the three and nine months ended September 30, 2026, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $1.0 million and $2.7 million, respectively, as reductions to product development and studies expense for services performed under the license agreement with Orion Corporation. For the three and nine months ended September 30, 2025, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $1.3 million and $3.8 million, respectively, as reductions to product development and studies expense for services performed under the license agreement with Orion Corporation. Refer to Note 4. Alliance and Collaboration.
(2)Kashiv’s R&D expenses were provided to the CODMs in total following the Kashiv Acquisition in the third quarter of 2026 and primarily consist of employee compensation and benefits, materials and supplies, product development and studies, and facilities costs.
(3)For the Affordable Medicines segment, other includes repairs and maintenance, outside testing, professional fees, equipment calibration and other expenses not presented to the CODMs. For the Specialty segment, other includes outside testing, professional fees and other expenses not presented to the CODMs.
v3.26.3
Property Losses and Associated Expenses
9 Months Ended
Sep. 30, 2026
Unusual or Infrequent Items, or Both [Abstract]  
Property Losses and Associated Expenses Property Losses and Associated Expenses
During the third week of July 2026, severe rain caused water damage to one of the Company’s facilities in India. Operations at this facility were temporarily suspended while the Company assessed the damage, completed remediation and repair activities, and restored operations. The Company concluded that certain property and equipment and inventory were damaged. The Company also incurred costs related to cleanup, repair and remediation. Accordingly, the Company recorded $5.4 million of charges related to inventory and property losses and associated cleanup, repair and remediation costs, comprised of the following (in thousands):
Three and Nine Months Ended September 30, 2026
Impairment of equipment$461 
Impairment of inventory4,574 
Repairs and maintenance and other expenses334 
Total property losses and associated expenses$5,369 
The Company maintains insurance coverage for property damage, inventory losses and business interruption. Insurance recoveries are recorded when realization is probable. No insurance recoveries have been recorded for the three and nine months ended September 30, 2026 in connection with this event.
v3.26.3
Leases
9 Months Ended
Sep. 30, 2026
Leases [Abstract]  
Leases Leases
Except as disclosed below, there were no material changes to the Company’s lease agreements as described in Note 16. Leases in the Company’s 2025 Annual Report on Form 10-K during the three and nine months ended September 30, 2026. The majority of the Company’s operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land.
In connection with the Kashiv Acquisition on August 10, 2026, the Company assumed certain operating leases that are significant to its operations. The significant leases acquired primarily consist of manufacturing sites, R&D facilities and warehouse space in the United States. The acquired leases assumed were recognized and measured at the acquisition date in accordance with ASC 805, Business Combinations, and ASC 842, Leases. As part of the preliminary purchase price allocation, the Company recognized operating lease right-of-use assets of approximately $33.9 million and operating lease liabilities of approximately $32.5 million related to the acquired leases, of which approximately $7.1 million and $5.2 million, respectively, relate to leases with related parties. Refer to Note 20. Related Party Transactions for additional information regarding the acquired related-party lease arrangements.
Any acquisition-date adjustments to the right-of-use assets for favorable or unfavorable lease terms relative to market were not material. Refer to Note 2. Acquisition for information regarding the preliminary operating lease right-of-use assets and lease liabilities recorded as of the acquisition date.
The tables below include information about the material operating leases assumed in the Kashiv Acquisition.
September 30, 2026
Weighted-average remaining lease term
7 years
Weighted-average discount rate
6.4%
Maturities of lease liabilities assumed as part of the Kashiv Acquisition as of September 30, 2026 were as follows (in thousands):
Operating Leases
Remainder of 2026
$1,839 
20277,349 
20287,061 
20294,230 
20303,064 
Thereafter17,624 
Total lease payments41,167 
Less: Imputed interest8,972 
Total$32,195 
Leases Leases
Except as disclosed below, there were no material changes to the Company’s lease agreements as described in Note 16. Leases in the Company’s 2025 Annual Report on Form 10-K during the three and nine months ended September 30, 2026. The majority of the Company’s operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land.
In connection with the Kashiv Acquisition on August 10, 2026, the Company assumed certain operating leases that are significant to its operations. The significant leases acquired primarily consist of manufacturing sites, R&D facilities and warehouse space in the United States. The acquired leases assumed were recognized and measured at the acquisition date in accordance with ASC 805, Business Combinations, and ASC 842, Leases. As part of the preliminary purchase price allocation, the Company recognized operating lease right-of-use assets of approximately $33.9 million and operating lease liabilities of approximately $32.5 million related to the acquired leases, of which approximately $7.1 million and $5.2 million, respectively, relate to leases with related parties. Refer to Note 20. Related Party Transactions for additional information regarding the acquired related-party lease arrangements.
Any acquisition-date adjustments to the right-of-use assets for favorable or unfavorable lease terms relative to market were not material. Refer to Note 2. Acquisition for information regarding the preliminary operating lease right-of-use assets and lease liabilities recorded as of the acquisition date.
The tables below include information about the material operating leases assumed in the Kashiv Acquisition.
September 30, 2026
Weighted-average remaining lease term
7 years
Weighted-average discount rate
6.4%
Maturities of lease liabilities assumed as part of the Kashiv Acquisition as of September 30, 2026 were as follows (in thousands):
Operating Leases
Remainder of 2026
$1,839 
20277,349 
20287,061 
20294,230 
20303,064 
Thereafter17,624 
Total lease payments41,167 
Less: Imputed interest8,972 
Total$32,195 
v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Repayment of Kashiv Rupee Term Loan
On October 1, 2026, the Company repaid the entire outstanding balance of $16.5 million under the Kashiv Rupee Term Loan Facility. The facility was subsequently terminated. Refer to Note 14. Debt for additional information.
2025 Revolving Credit Facility
On October 30, 2026, the Company repaid $50.0 million of the $180.0 million outstanding under the 2025 Revolving Credit Facility as of September 30, 2026.
Rondo Redeemable Non-Controlling Interests
On September 15, 2026, the Company entered into an equity purchase agreement to acquire a portion of the outstanding Rondo Class B Units for cash consideration of $19.8 million. The transaction closed on October 1, 2026 and increased the Company’s ownership interest in AvKARE, LLC and R&S from 65.1% to 66.4%. Refer to Note 19. Stockholders’ Equity (Deficiency) for additional information.
Leases
During the third quarter of 2026, the Company entered into a ten-year lease agreement for a manufacturing and warehouse facility in New Jersey, which commenced in October 2026. The aggregate lease payments over the lease term are approximately $49.6 million, net of lease incentives.
On October 5, 2026, the Company executed an amendment to its corporate headquarters lease in New Jersey to expand the leased premises and extend the lease term through November 30, 2031. The aggregate lease payments over the amended lease term are approximately $19.9 million.
v3.26.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The interim unaudited consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission and U.S. generally accepted accounting principles (“U.S. GAAP”) for interim reporting. These financial statements include all adjustments that in the opinion of management are necessary for a fair presentation of the financial position, results of operations, and cash flows of Amneal Pharmaceuticals, Inc. (the “Company”) for the periods presented. However, these financial statements do not include all information and accompanying notes required for annual financial statements prepared in accordance with U.S. GAAP. The interim unaudited consolidated financial statements should be read in conjunction with the audited annual financial statements included in the Company’s 2025 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of financial statements requires the Company’s management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning December 15, 2027, with early adoption permitted. Upon adoption, ASU 2024-03 may be applied prospectively for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Revenue Recognition
The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers. The majority of the Company’s revenue is recognized from shipping products to customers. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements. These agreements generally obligate the Company to provide R&D services over multiple periods.
v3.26.3
Acquisition (Tables)
9 Months Ended
Sep. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Preliminary Consideration Transferred
The preliminary fair value of consideration transferred is summarized as follows (in thousands):
Cash consideration (1)
$266,066
Equity consideration (2)
491,610
Fair value of contingent consideration – milestone payments (3)
137,000
Fair value of contingent consideration – royalty payments (4)
252,000
Repayment of certain Kashiv debt obligations (5)
162,180
Receivable from sellers related to purchase price adjustment (6)
(1,814)
Settlement of pre-existing relationship (7)
(4,556)
Preliminary fair value of consideration transferred$1,302,486
(1)The cash consideration paid at closing of $266.1 million reflects the initial cash consideration of $375.0 million, less $180.0 million of indebtedness and $3.0 million of transaction expenses, plus $3.9 million of estimated closing cash, $66.7 million of working capital adjustments and $3.5 million of prepayment adjustments, each as determined pursuant to the terms of the Purchase Agreement. Certain amounts remain subject to customary post-closing adjustments.
(2)The Company issued 28.9 million shares of its Class A common stock to the sellers of Kashiv. The fair value of the equity consideration was based on the $17.88 closing price of the Company’s Class A common stock on NASDAQ on August 10, 2026, adjusted by a 5% discount for lack of marketability reflecting temporary transfer restrictions associated with the then-unregistered shares.
(3)The sellers of Kashiv are eligible to receive up to $350.0 million in contingent milestone payments upon the achievement of certain regulatory milestones in the United States for up to six designated Kashiv product candidates (consisting of up to $250.0 million for the first tranche of designated products and up to $100.0 million for the second tranche of designated products). The preliminary fair value of the contingent consideration for milestone payments on the acquisition date of approximately $137.0 million was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, probability of achievement of milestones, and projected year of payments. Refer to Note 16. Fair Value Measurements for additional information on the methodology and determination of this liability.
(4)The sellers of Kashiv are also eligible to receive, during the 12-year period following the acquisition date, royalty payments equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty period. The preliminary fair value of the contingent consideration for royalty payments on the acquisition date of approximately $252.0 million was based on significant Level 3 inputs that were not observable in the market. Key assumptions included projected future gross profits for the underlying products, the timing and probability of expected payments, and the discount rate applied to the estimated future cash flows. Refer to Note 16. Fair Value Measurements for additional information on the methodology and determination of this liability.
(5)Represents amounts paid at closing to repay certain debt obligations of Kashiv, including related prepayment amounts.
(6)Represents an estimated amount due from the sellers related to post-closing purchase price adjustments.
(7)The pre-existing balances between the Company and Kashiv were effectively settled upon completion of the acquisition.
Schedule of Preliminary Purchase Price Allocation for the Acquisitions
The initial accounting for the acquisition remains incomplete, primarily related to the valuation of certain acquired assets and liabilities, including working capital, property, plant and equipment, intangible assets and contingent consideration, due to the
proximity of the acquisition date to the balance sheet date of September 30, 2026. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):
Preliminary Fair Values as of
August 10, 2026
Cash and cash equivalents$3,111
Inventories (1)
22,215
Prepaid expenses and other current assets12,034
Related party receivables234
Property, plant and equipment (2)
111,584
Goodwill179,478
Intangible assets1,003,000
Operating lease right-of-use assets26,798
Operating lease right-of-use assets - related party (3)
7,143
Other assets (4)
14,299
Total assets acquired1,379,896
Accounts payable and accrued expenses28,838
Current portion of operating lease liabilities4,605
Current portion of operating lease liabilities - related party412
Related party payables - short term64
Long-term debt, net15,137
Operating lease liabilities22,687
Operating lease liabilities - related party4,768
Other long-term liabilities899
Total liabilities assumed77,410
Preliminary fair value of consideration transferred$1,302,486
(1)Includes a $6.5 million inventory fair value step-up adjustment, which will be recognized in cost of goods sold as the related inventory is sold.
(2)Includes a $10.9 million fair value step-up adjustment for acquired property, plant and equipment from its historical carrying value to its preliminary fair value, which will be recognized over the remaining service lives of the assets as depreciation expense.
(3)Includes a $2.0 million adjustment to reflect favorable lease terms relative to market.
(4)Includes $4.1 million of long-term restricted cash.
Schedule of Acquired Intangible Assets
The preliminary fair values and estimated useful lives of identifiable intangible assets acquired as of August 10, 2026 were as follows (in thousands):
Preliminary Fair ValueWeighted-Average
Useful Life
(in years)
In-process research and development (“IPR&D”) (1)
$963,000
Indefinite (2)
Marketed product rights40,0009.0
Fair value of identifiable intangible assets acquired$1,003,000
(1)During September 2026, following the regulatory approval and launch of lanreotide, the related acquired IPR&D was reclassified to marketed product rights and began amortizing over an estimated useful life of approximately five years.
(2)IPR&D assets are considered indefinite‑lived until completion or abandonment of the related projects and are not amortized during the development period. Upon commercialization, the Company will determine a useful life and begin amortization.
Schedule of Pro Forma Information
The unaudited pro forma combined results of operations for the three and nine months ended September 30, 2026 and 2025
(assuming the closing of the Kashiv Acquisition occurred on January 1, 2025) were as follows (in thousands):

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net revenue$862,918$793,555$2,386,897$2,216,607
Net income (loss)$8,411$(22,748)$61,380$(43,119)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest$(11,351)$(38,511)$13,922$(84,498)
v3.26.3
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Major Customers by Reporting Segments
The following table summarizes revenues from each of the Company’s customers that individually accounted for 10% or more of its total net revenue in any of the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Customer A25 %23 %24 %24 %
Customer B16 %14 %16 %15 %
Customer C21 %22 %21 %21 %
Customer D
7 %10 %8 %9 %
Schedule of Disaggregated Revenue The Company’s significant dosage forms within its Affordable Medicines segment, therapeutic classes within its Specialty segment, and sales channels within its AvKARE segment, each determined based on net revenue for the three and nine months ended September 30, 2026 and 2025, are presented below (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Affordable Medicines
Oral solid$207,517 $180,460 $553,789 $537,675 
Transdermal68,066 47,599 209,067 131,372 
Auto-Injector65,163 78,940 169,289 193,694 
Injectable53,805 54,368 160,526 123,802 
Biosimilar77,710 17,009 129,139 70,797 
Oral liquid9,092 16,415 31,555 57,842 
Other dosage forms (1)
60,841 59,662 189,047 184,269 
Subtotal dosage forms542,194 454,453 1,442,412 1,299,451 
International4,915 6,288 17,847 9,423 
Total Affordable Medicines net revenue547,109 460,741 1,460,259 1,308,874 
Specialty
Central nervous system96,177 77,631 274,904 228,666 
Hormonal / allergy43,148 37,685 121,179 107,302 
Other therapeutic classes9,449 9,924 35,251 25,112 
Subtotal therapeutic classes148,774 125,240 431,334 361,080 
License agreement1,488 — 1,488 500 
Total Specialty net revenue150,262 125,240 432,822 361,580 
AvKARE
Distribution92,905 96,216 268,984 300,774 
Government label53,385 87,755 163,541 183,313 
Institutional10,012 5,853 31,943 26,994 
Other9,011 8,708 23,851 22,906 
Total AvKARE net revenue165,313 198,532 488,319 533,987 
Total net revenue$862,684 $784,513 $2,381,400 $2,204,441 
(1)Includes net revenue from sales of transmucosal, ophthalmic, topical, nasal and inhalation dosage forms.
Schedule of Major Categories of Sales-Related Deductions
A rollforward of the major categories of sales-related deductions for the nine months ended September 30, 2026 is as follows (in thousands):
Contract
Charge - Backs
and Sales
Volume
Allowances
Cash Discount
Allowances
Accrued
Returns
Allowance
Accrued
Medicaid and
Commercial
Rebates
Balance at December 31, 2025$801,186 $40,992 $179,471 $119,486 
Provision related to sales recorded in the period3,161,376 107,663 60,770 135,010 
Credits/payments issued during the period(3,427,057)(116,413)(48,728)(184,184)
Balance at September 30, 2026$535,505 $32,242 $191,513 $70,312 
v3.26.3
Alliance and Collaboration (Tables)
9 Months Ended
Sep. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Company’s Alliance and Collaboration Agreements
The following table summarizes certain amounts recognized in the Company’s consolidated statements of operations related to alliance and collaboration agreements for the three and nine months ended September 30, 2026 and 2025 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
PartyCaption in Statement of Operations2026202520262025
Orion Corporation
Research and development (1)
$(776)$(912)$(1,883)$(2,677)
Orion Corporation
Research and development (2)
$(197)$(372)$(818)$(1,131)
Pfizer Inc. (formerly Metsera, Inc.)
Other operating income (3)
$— $— $(6,877)$— 
Pfizer Inc. (formerly Metsera, Inc.)
Net revenue (4)
$— $245 $— $2,218 
Zambon Biotech S.A.
Net revenue (5)
$1,488 $— $1,488 $— 
(1)Deferred income was recognized as a reduction to R&D expense as services were performed under the Orion Agreement.
(2)Reimbursable R&D services performed under the Orion Agreement were recorded as a reduction to R&D expense.
(3)Gain from derecognizing financing obligation (refer to the Pfizer Collaboration Agreement section below).
(4)Development activities performed on behalf of Pfizer, Inc. on a cost plus margin basis are recorded as net revenue.
(5)Net revenue was recognized for achievement of a regulatory approval milestone.
The following table summarizes certain balances recognized in the Company’s consolidated balance sheets related to alliance and collaboration agreements as of September 30, 2026 and December 31, 2025 (in thousands):
PartyCaption in Balance SheetSeptember 30, 2026December 31, 2025
Orion Corporation
Accounts payable and accrued expenses (1)
$3,445 $4,811 
Orion Corporation
Other long-term liabilities (1)
$296 $814 
Zambon Biotech S.A.
Other long-term liabilities (1)
$2,725 $2,530 
Zambon Biotech S.A.
Accounts payable and accrued expenses (1)
$641 $— 
mAbxience S.L.
Accounts payable and accrued expenses (2)
$— $7,500 
Pfizer Inc. (formerly Metsera, Inc.)
Prepaid expenses and other current assets (3)
$— $321 
Pfizer Inc. (formerly Metsera, Inc.)
Other long-term liabilities (4)
$22,415 $9,378 
(1)Comprised of deferred income as of September 30, 2026 and December 31, 2025.
(2)Comprised of an accrued milestone as of December 31, 2025 for a Food and Drug Administration (“FDA”) approval.
(3)Comprised primarily of unbilled receivables for R&D services performed as of December 31, 2025.
(4)Comprised of construction costs contributed, as defined in the Company’s collaboration agreement with Pfizer Inc. (“Pfizer”). As of September 30, 2026, the funding received from Pfizer represented a contract obligation for future manufacturing services (deferred income). As of December 31, 2025, the funding received from Pfizer was allocated between two performance obligations: (i) a financing obligation in accordance with ASC 470, Debt of $6.4 million and (ii) a contract obligation for future manufacturing services of $3.0 million (refer to the Pfizer Collaboration Agreement section below).
v3.26.3
Income Taxes (Tables)
9 Months Ended
Sep. 30, 2026
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes
Set forth in the following table is the Company’s provision for (benefit from) income taxes (in thousands) and effective tax rate:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Provision for (benefit from) income taxes$2,751 $(23,355)$6,303 $5,614 
Effective tax rate18.3 %447.2 %3.8 %6.7 %
Schedule of Tax Receivable Agreement
The following table summarizes the Company’s tax receivable agreement (“TRA”) (in thousands):
Statements of Operations
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Increase (decrease) in tax receivable agreement liability$12,992 $(20,808)$13,098 $(5,701)
September 30, 2026December 31, 2025
Tax receivable agreement liability - short term (1)
$16,323 $38,832 
Tax receivable agreement liability - long term (1)
15,432 18,656 
Total$31,755 $57,488 
(1) Refer to Note 20. Related Party Transactions.
v3.26.3
(Loss) Earnings per Share (Tables)
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings per Share
The computation of basic and diluted (loss) earnings per share was as follows (in thousands, except per share amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Numerator:
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.
$(21,695)$2,369 $98,223 $36,981 
Denominator:
Weighted-average shares outstanding - basic335,733 314,168 323,724 312,998 
Effect of dilutive securities:
Stock options— 882 767 981 
Restricted stock units— 4,129 4,192 4,303 
Performance stock units— 5,575 6,550 5,422 
Weighted-average shares outstanding - diluted335,733 324,754 335,233 323,704 
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic$(0.06)$0.01 $0.30 $0.12 
Diluted$(0.06)$0.01 $0.29 $0.11 
Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share
The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Stock options
1,153 
(1)
347 
(2)
— 347 
(2)
Restricted stock units6,908 
(1)
— — — 
Performance stock units
6,571 
(1)
1,960 
(3)
— 1,960 
(3)
(1)Excluded from the computation of diluted loss per share of Class A common stock because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company during the period.
(2)Excluded from the computation of diluted earnings per share of Class A common stock because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money).
(3)Excluded from the computation of diluted earnings per share of Class A common stock because the performance vesting conditions were not met during the period.
v3.26.3
Trade Accounts Receivable, Net (Tables)
9 Months Ended
Sep. 30, 2026
Receivables [Abstract]  
Schedule of Trade Accounts Receivable, Net
Trade accounts receivable, net was comprised of the following (in thousands):
September 30, 2026December 31, 2025
Gross accounts receivable$1,591,921 $1,740,324 
Allowance for credit losses(7,330)(3,003)
Contract charge-backs and sales volume allowances(535,505)(801,186)
Cash discount allowances(32,242)(40,992)
Subtotal(575,077)(845,181)
Trade accounts receivable, net$1,016,844 $895,143 
Schedules of Percent of Gross Trade Receivables
Trade accounts receivable from customers representing 10% or more of the Company’s total trade accounts receivable were as follows:
September 30, 2026December 31, 2025
Customer A39 %39 %
Customer B25 %23 %
Customer C24 %26 %
v3.26.3
Inventories (Tables)
9 Months Ended
Sep. 30, 2026
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
Inventories were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Raw materials$286,654 $227,353 
Work in process78,098 55,455 
Finished goods343,204 323,494 
Total inventories$707,956 $606,302 
v3.26.3
Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Deposits and advances$4,812 $4,437 
Prepaid insurance6,787 6,723 
Prepaid regulatory fees10,791 8,109 
Income and other tax receivables24,454 18,662 
Prepaid taxes14,482 17,068 
Accrued royalty income (1)
84,069 14,332 
Other current receivables9,440 5,295 
Chargebacks receivable7,815 5,972 
Other prepaid assets34,119 17,797 
Total prepaid expenses and other current assets$196,769 $98,395 
(1)The increase in accrued royalty income primarily reflects profit share income under the ALYMSYS® distribution agreement with Valorum Oncology, LLC, as described in Note 4. Alliance and Collaboration in the Company’s 2025 Annual Report on Form 10-K.
v3.26.3
Property, Plant, and Equipment, Net (Tables)
9 Months Ended
Sep. 30, 2026
Property, Plant, and Equipment [Abstract]  
Schedule of Property, Plant and Equipment, Net Estimated Useful Lives
Property, plant, and equipment, net was comprised of the following (in thousands):
September 30, 2026December 31, 2025
Land$20,559 $19,690 
Buildings234,777 234,599 
Leasehold improvements153,184 133,833 
Machinery and equipment546,778 473,076 
Furniture and fixtures17,574 16,170 
Vehicles2,282 2,018 
Computer equipment83,100 76,825 
Construction-in-progress147,773 92,909 
Total property, plant, and equipment1,206,027 1,049,120 
Less: Accumulated depreciation(633,393)(606,170)
Property, plant, and equipment, net$572,634 $442,950 
v3.26.3
Goodwill and Other Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Schedule of Changes in Goodwill by Segment
The changes in goodwill by segment were as follows (in thousands):
Affordable MedicinesSpecialtyAvKARETotal
Balance as of December 31, 2024$161,659 $366,312 $69,465 $597,436 
Currency translation(1,966)— — (1,966)
Balance as of December 31, 2025159,693 366,312 69,465 595,470 
Goodwill acquired during the period179,478 — — 179,478 
Currency translation(2,475)— — (2,475)
Balance as of September 30, 2026$336,696 $366,312 $69,465 $772,473 
Schedule of Intangible Assets
Intangible assets as of September 30, 2026 and December 31, 2025 were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Weighted-Average
Amortization Period
(in years)
CostAccumulated
Amortization
NetCostAccumulated
Amortization
Net
Amortizing intangible assets:
Product rights5.8$1,768,413 $(1,071,688)$696,725 $1,519,694 $(977,819)$541,875 
Other intangible assets1.982,700 (77,270)5,430 82,700 (69,177)13,523 
Total1,851,113 (1,148,958)702,155 1,602,394 (1,046,996)555,398 
IPR&D
849,100 — 849,100 8,100 — 8,100 
Total intangible assets$2,700,213 $(1,148,958)$1,551,255 $1,610,494 $(1,046,996)$563,498 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The following table presents future amortization expense for the next five years and thereafter, excluding $849.1 million of IPR&D intangible assets (in thousands):
Future Amortization
Remainder of 2026$45,026 
2027162,946 
2028117,468 
2029104,765 
2030105,989 
203192,587 
Thereafter73,374 
Total$702,155 
v3.26.3
Other Assets (Tables)
9 Months Ended
Sep. 30, 2026
Other Assets [Abstract]  
Schedule of Other Assets
Other assets were comprised of the following (in thousands): (1)
September 30, 2026December 31, 2025
Interest rate swap (2)
$33,775 $5,756 
Security deposits4,811 3,932 
Long-term deposits and prepaid expenses2,437 3,412 
Deferred revolving credit facility costs 4,331 5,197 
Long-term restricted cash8,680 2,068 
Equipment deposits48,068 34,332 
Other long-term assets 20,705 3,108 
Total other assets$122,807 $57,805 
(1)Certain prior period amounts have been reclassified to conform to the current period presentation. As of September 30, 2026, the Company separately presented equipment deposits within other assets to provide additional transparency regarding the nature of these balances. Such reclassifications had no impact on total other assets, total assets, results of operations, or cash flows.
(2)Refer to Note 16. Fair Value Measurements and Note 17. Financial Instruments for information about the Company’s interest rate swap.
v3.26.3
Accounts Payable and Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2026
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Accounts payable$283,662 $254,671 
Accrued returns allowance (1)
191,513 179,471 
Accrued compensation90,790 79,886 
Accrued Medicaid and commercial rebates (1)
70,312 119,486 
Accrued royalties72,981 30,040 
Accrued professional fees20,904 14,514 
Accrued interest8,530 18,663 
Accrued other50,139 64,585 
Total accounts payable and accrued expenses$788,831 $761,316 
(1)Refer to Note 3. Revenue Recognition for a rollforward of the balance from December 31, 2025 to September 30, 2026.
v3.26.3
Debt (Tables)
9 Months Ended
Sep. 30, 2026
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
The following is a summary of the Company’s long-term debt, including the current portion (in thousands):
September 30, 2026December 31, 2025
Term Loan Due 2032$2,434,263 $2,094,750 
Senior Notes Due 2032600,000 600,000 
Kashiv Rupee Term Loan Facility16,484 — 
Total debt3,050,747 2,694,750 
Less: debt issuance costs(111,313)(122,874)
Total debt, net of debt issuance costs2,939,434 2,571,876 
Less: current portion of long-term debt(23,933)(6,761)
Total long-term debt, net$2,915,501 $2,565,115 
v3.26.3
Other Long-Term Liabilities (Tables)
9 Months Ended
Sep. 30, 2026
Other Liabilities Disclosure [Abstract]  
Schedule of Other Long-Term Liabilities
Other long-term liabilities were comprised of the following (in thousands):
September 30, 2026December 31, 2025
Long-term compensation$9,847 $11,354 
Deferred income (1)
26,598 7,324 
Other long-term liabilities1,352 13,585 
Total other long-term liabilities$37,797 $32,263 
(1)Deferred income was primarily from alliance and collaboration agreements with Orion Corporation, Zambon Biotech S.A., and Pfizer. Refer to Note 4. Alliance and Collaboration for additional information.
v3.26.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table sets forth the Company’s financial assets that were measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 (in thousands):
Fair Value Measurement Based on
September 30, 2026TotalQuoted
Prices in
Active
Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Assets
Interest rate swap (1)
$33,775 $— $33,775 $— 
Liabilities
Contingent consideration liability (2)
$383,000 $— $— $383,000 
December 31, 2025
Assets
Interest rate swap (1)
$5,756 $— $5,756 $— 
(1)The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial
information and certain assumptions regarding past, present, and future market conditions. Refer to Note 17. Financial Instruments for information on the Company’s interest rate swap.
(2)The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of September 30, 2026, the contingent consideration liability associated with the Kashiv Acquisition of $383.0 million recorded in the Company’s consolidated balance sheet included $59.0 million in contingent consideration - related party - short term and $324.0 million in contingent consideration - related party - long-term. Refer to Note 2. Acquisition and Note 20. Related Party Transactions for additional information associated with the Kashiv Acquisition.
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
Nine Months Ended September 30, 2026
Balance, December 31, 2025$— 
Addition due to the Kashiv Acquisition389,000 
Change in fair value during period(6,000)
Balance, September 30, 2026$383,000 
Schedule of Fair Value Measurement Inputs and Valuation Techniques
The following table summarizes the significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration liabilities as of September 30, 2026:
Contingent Consideration Liability
Fair Value as of
September 30, 2026
(in thousands)
Valuation TechniqueUnobservable inputRange
Weighted Average (1)
Regulatory Milestones
$135,000Probability-weighted discounted cash flowDiscount rate5.8%–6.8%6.2%
Probability of payment20.2%–92.5%63.0%
Projected year of payment2027–20312029
Royalties
$248,000Monte Carlo SimulationDiscount rate5.4%–7.6%6.8%
Volatility25.0%–25.0%25.0%
Probability of payment (2)
20.2%–92.5%63.0%
Projected year of payment (3)
2027–20382032
(1)Unobservable inputs were weighted by the relative fair value of each product candidate acquired.
(2)Excludes three products that have all successfully launched as of September 30, 2026 and have a 100% probability of payment.
(3)Projected year of payment represents the estimated timing of royalty payments utilized in the Monte Carlo Simulation valuation model. Payments are expected to occur from 2027 through 2038, with approximately 50% of discounted expected payments occurring by 2032.
Schedule of the Company’s Indebtedness at Fair Value
The following is a summary of the Company’s indebtedness at fair value (in thousands):
September 30, 2026December 31, 2025
Term Loan Due 2032$2,446,434 $2,115,698 
Senior Notes Due 2032$601,500 $633,000 
v3.26.3
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets
A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands):
September 30, 2026December 31, 2025
Derivatives Designated as Hedging InstrumentsBalance Sheet
Classification
Fair ValueBalance Sheet
Classification
Fair Value
Variable-to-fixed interest rate swapOther Assets$33,775 Other Assets$5,756 
v3.26.3
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Liabilities Related to Legal Matters
Liabilities for legal matters were comprised of the following (in thousands):
MatterSeptember 30, 2026December 31, 2025
Civil prescription opioid litigation (1)
$9,454 $42,271 
Government investigations8,000 — 
Antitrust class action litigation7,450 — 
Other
2,630 985 
Current portion of liabilities for legal matters$27,534 $43,256 
Civil prescription opioid litigation (Liabilities for legal matters - long term) (1)
$71,663 $71,819 
(1)As of September 30, 2026, the total current and long-term liabilities of $81.1 million for civil prescription opioid litigation were primarily comprised of an $80.6 million liability for the Nationwide Opioids Settlement Agreement effective January 23, 2026, as defined and described in the section Civil Prescription Opioid Litigation below. Of the $80.6 million accrued for this settlement agreement, $79.7 million was for cash payments and $0.9 million was for the supply of naloxone nasal spray.
Schedule of Cash Payments
As of September 30, 2026, the remaining cash payments under the Nationwide Opioids Settlement Agreement, due on March 1 of each year, were as follows (in thousands):
Amount Due
2027$12,670 
202812,389 
202912,389 
203012,389 
2031 (1)
11,939 
2032 to 2034 (1)
35,816 
Total settlement payments$97,592 
Less: imputed interest at a rate of 5.5%
(17,917)
Total $79,675 
(1)Amounts due in each of 2031 through 2034 include approximately $10.4 million of cash conversion payments associated with certain settling parties’ elections to receive cash in lieu of naloxone nasal spray under the Nationwide Opioids Settlement Agreement ($41.4 million in the aggregate).
v3.26.3
Stockholders’ Equity (Deficiency) (Tables)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Loss by Component
Changes in accumulated other comprehensive loss by component were as follows (in thousands):
Foreign
currency
translation
adjustments
Unrealized (loss) gain on cash
flow hedge, net
of tax
OtherAccumulated
other
comprehensive loss
December 31, 2025$(90,545)$(14,844)$(5,340)$(110,729)
Other comprehensive (loss) gain before reclassification(13,332)28,019 4,228 18,915 
Reclassification of cash flow hedge to earnings, net of tax of $0
— 8,730 — 8,730 
September 30, 2026$(103,877)$21,905 $(1,112)$(83,084)
December 31, 2024$(71,860)$6,350 $— $(65,510)
Other comprehensive loss before reclassification(15,648)(23,011)— (38,659)
Reclassification of cash flow hedge to earnings, net of tax of $0
— (1,714)— (1,714)
September 30, 2025$(87,508)$(18,375)$— $(105,883)
v3.26.3
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations2026202520262025
Kashiv (1)
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$1,654 $3,353 $7,533 $11,148 
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$407 $3,602 $5,042 $9,218 
Generic development supply agreement - recognition of deferred incomeResearch and development$(163)$— $(163)$— 
Development and commercialization agreement - OmalizumabResearch and development$— $22,500 $— $22,500 
Generic development supply agreement - research and development materialResearch and development$— $(502)$— $(502)
Storage agreementResearch and development$— $(71)$— $(189)
Development and commercialization agreement - Pegfilgrastim Auto Injector - milestoneResearch and development$— $— $500 $3,000 
Development and commercialization agreement - CarfilzomibResearch and development$— $— $— $2,000 
Parking space leaseResearch and development$— $— $— $25 
Generic development supply agreement - development activity deferred incomeAccounts payable and
accrued expenses
$— $— $— $(99)
Other Related Parties
Members - tax receivable agreementIncrease (decrease) in tax receivable agreement liability$12,992 $(20,808)$13,098 $(5,701)
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,067 $4,634 $16,218 $15,973 
Sellers of Kashiv - change in fair value of contingent consideration (2)
Change in fair value of contingent consideration$(6,000)$— $(6,000)$— 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$861 $185 $2,545 $2,512 
Kanan, LLC - operating leaseInventory and cost of goods sold$654 $592 $1,938 $1,776 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$405 $333 $1,143 $987 
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expenseCost of goods sold$314 $— $1,178 $— 
Direct Customer Solutions, LLC - warehousing/logistics/distribution servicesSelling, general and administrative$166 $— $295 $— 
Twenty NEA, LLC - operating lease (3)
Cost of goods sold$104 $— $104 $— 
Tracy Properties LLC - operating leaseSelling, general and administrative$81 $152 $248 $478 
Avtar Investments, LLC - consulting servicesResearch and development$60 $60 $180 $180 
AvPROP, LLC - operating leaseSelling, general and administrative$48 $46 $130 $150 
Avtar Investments, LLC - office rental space (3)
Selling, general and administrative$34 $— $34 $— 
Land purchase from family members of the Co-Chief Executive OfficersProperty, plant and equipment$— $— $— $11,289 
Ellodi Pharmaceuticals, L.P. - securities purchase and license and collaboration agreementsResearch and development$— $338 $— $6,046 
R&S Solutions - equipment purchaseProperty, plant and equipment$— $47 $— $207 
Alkermes PlcInventory and cost of goods sold$— $3 $— $67 
(1)Amounts relate to agreements previously between Amneal and Kashiv that were acquired in the Kashiv Acquisition and, following the closing of the transaction on August 10, 2026, became transactions among Amneal’s consolidated subsidiaries. Accordingly, the amounts presented for the three and nine months ended September 30, 2026 reflect activity only through August 10, 2026.
(2)Represents changes in the fair value of contingent consideration liabilities payable to the sellers of Kashiv pursuant to the Purchase Agreement.
(3)These agreements were acquired in the Kashiv Acquisition and are included in the Company’s related party disclosures for the three and nine months ended September 30, 2026 because the counterparties meet the definition of related parties. The amounts presented reflect activity from the acquisition date through September 30, 2026.
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
September 30, 2026December 31, 2025
Preliminary working capital adjustment - sellers of Kashiv$1,814 $— 
AzaTech Pharma LLC62 56 
Kashiv - various agreements— 413 
Apace Packaging, LLC - packaging agreement— 1 
Related party receivables - short term $1,876 $470 
Members - tax receivable agreement$16,323 $38,832 
Apace Packaging, LLC - packaging agreement1,640 1,353 
AzaTech Pharma LLC - supply agreement505 254 
PharmaSophia, LLC - license and commercialization agreement314 — 
Avtar Investments LLC - consulting services74 40 
Direct Customer Solutions, LLC57 — 
Kashiv - various agreements— 14,980 
Tracy Properties LLC— 26 
Related party payables - short term $18,913 $55,485 
Members - tax receivable agreement$15,432 $18,656 
Land purchase from family members of the Co-Chief Executive Officers446 476 
Related party payables - long term $15,878 $19,132 
v3.26.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, research and development expenses, and other operating expenses to the extent specifically identified by segment (in thousands):
Three Months Ended September 30, 2026
Affordable Medicines (1)
SpecialtyAvKARECorporate
and Other
Total
Company
Net revenue$547,109 $150,262 $165,313 $— $862,684 
Cost of goods sold352,331 46,212 130,023 — 528,566 
Gross profit194,778 104,050 35,290 — 334,118 
Selling, general and administrative32,097 36,969 A17,919 52,660 139,645 
Research and development63,418 B4,956 B— — 68,374 
Intellectual property legal development expenses2,138 55 — — 2,193 
Acquisition and integration costs— — — 22,320 22,320 
Restructuring and other charges891 — — 45 936 
Change in fair value of contingent consideration(6,000)— — — (6,000)
Charges for property losses and associated expenses5,334 35 — — 5,369 
Charges (credit) related to legal matters, net
5,500 1,000 — (3)6,497 
Other operating income(631)— — — (631)
Operating income (loss)$92,031 $61,035 $17,371 $(75,022)$95,415 
Nine Months Ended September 30, 2026
Affordable Medicines (1)
SpecialtyAvKARECorporate
and Other
Total
Company
Net revenue$1,460,259 $432,822 $488,319 $— $2,381,400 
Cost of goods sold867,459 137,497 387,705 — 1,392,661 
Gross profit592,800 295,325 100,614 — 988,739 
Selling, general and administrative115,782 111,755 A51,512 148,178 427,227 
Research and development129,727 B16,047 B— — 145,774 
Intellectual property legal development expenses5,633 189 — — 5,822 
Acquisition and integration costs— — — 35,073 35,073 
Restructuring and other charges891 347 — 902 2,140 
Change in fair value of contingent consideration(6,000)— — — (6,000)
Charges for property losses and associated expenses5,334 35 — — 5,369 
Charges (credit) related to legal matters, net
14,251 1,000 — (3)15,248 
Other operating income(8,870)— — — (8,870)
Operating income (loss)$336,052 $165,952 $49,102 $(184,150)$366,956 
Three Months Ended September 30, 2025
Affordable Medicines (1)
SpecialtyAvKARE Corporate
and Other
Total
Company
Net revenue$460,741 $125,240 $198,532 $— $784,513 
Cost of goods sold280,463 73,808 156,268 — 510,539 
Gross profit180,278 51,432 42,264 — 273,974 
Selling, general and administrative37,173 33,580 A15,234 51,828 137,815 
Research and development55,124 B8,228 B— — 63,352 
Intellectual property legal development expenses2,378 59 — — 2,437 
Restructuring and other charges90 — — 53 143 
Other operating income(117)— — — (117)
Operating income (loss)$85,630 $9,565 $27,030 $(51,881)$70,344 
Nine Months Ended September 30, 2025
Affordable Medicines (1)
SpecialtyAvKARE Corporate
and Other
Total
Company
Net revenue$1,308,874 $361,580 $533,987 $— $2,204,441 
Cost of goods sold775,742 182,686 429,895 — 1,388,323 
Gross profit533,132 178,894 104,092 — 816,118 
Selling, general and administrative105,114 94,872 A46,007 134,376 380,369 
Research and development128,003 B23,353 B— — 151,356 
Intellectual property legal development expenses6,069 152 — — 6,221 
Restructuring and other charges773 471 — 494 1,738 
Credit related to legal matters, net(390)— — — (390)
Other operating income(5,239)— — — (5,239)
Operating income (loss)$298,802 $60,046 $58,085 $(134,870)$282,063 
(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in Affordable Medicines.
Significant Expense Categories Provided to the Chief Operating Decision Makers
Selling, General and Administrative Expenses - Specialty Segment
A.The CODMs review certain selling, general and administrative expenses (“SG&A”) for the Specialty segment and, separately, on a departmental basis. The CODMs review SG&A for the Affordable Medicines and AvKARE segments in total. SG&A for the Specialty segment was comprised of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Employee compensation and benefits$13,315 $10,972 $38,188 $32,635 
Product marketing10,231 11,273 32,039 29,168 
Commercial operations and salesforce12,951 9,769 38,326 29,347 
Other (1)
472 1,566 3,202 3,722 
Total$36,969 $33,580 $111,755 $94,872 
(1)Other includes professional fees and other expenses not presented to the CODMs.
Research and Development Expenses - Affordable Medicines and Specialty Segments
B.Research and development expenses for the Affordable Medicines and Specialty segments were comprised of the following (in thousands):
Three Months Ended September 30,
20262025
Affordable MedicinesSpecialtyAffordable MedicinesSpecialty
Employee compensation and benefits$12,343 $1,658 $13,905 $1,089 
Materials and supplies6,944 842 6,230 1,358 
Product development and studies (1)
127 1,715 673 2,823 
In-licensing and upfront milestones— — 22,500 — 
Facilities costs1,654 45 1,755 409 
Regulatory fees704 — 2,317 — 
Kashiv R&D expenses (2)
19,421 — — — 
Other (3)
22,225 696 7,744 2,549 
Total$63,418 $4,956 $55,124 $8,228 
Nine Months Ended September 30,
20262025
Affordable MedicinesSpecialtyAffordable MedicinesSpecialty
Employee compensation and benefits$37,382 $4,303 $42,139 $3,908 
Materials and supplies24,555 1,924 22,865 2,011 
Product development and studies (1)
963 7,108 1,360 7,513 
In-licensing and upfront milestones4,000 — 29,100 3,000 
Facilities costs4,623 110 5,182 1,894 
Regulatory fees4,432 — 4,834 — 
Kashiv R&D expenses (2)
19,421 — — — 
Other (3)
34,351 2,602 22,523 5,027 
Total$129,727 $16,047 $128,003 $23,353 
(1)For the three and nine months ended September 30, 2026, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $1.0 million and $2.7 million, respectively, as reductions to product development and studies expense for services performed under the license agreement with Orion Corporation. For the three and nine months ended September 30, 2025, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $1.3 million and $3.8 million, respectively, as reductions to product development and studies expense for services performed under the license agreement with Orion Corporation. Refer to Note 4. Alliance and Collaboration.
(2)Kashiv’s R&D expenses were provided to the CODMs in total following the Kashiv Acquisition in the third quarter of 2026 and primarily consist of employee compensation and benefits, materials and supplies, product development and studies, and facilities costs.
(3)For the Affordable Medicines segment, other includes repairs and maintenance, outside testing, professional fees, equipment calibration and other expenses not presented to the CODMs. For the Specialty segment, other includes outside testing, professional fees and other expenses not presented to the CODMs.
v3.26.3
Property Losses and Associated Expenses (Tables)
9 Months Ended
Sep. 30, 2026
Unusual or Infrequent Items, or Both [Abstract]  
Schedule of Property Losses and Associated Expenses Accordingly, the Company recorded $5.4 million of charges related to inventory and property losses and associated cleanup, repair and remediation costs, comprised of the following (in thousands):
Three and Nine Months Ended September 30, 2026
Impairment of equipment$461 
Impairment of inventory4,574 
Repairs and maintenance and other expenses334 
Total property losses and associated expenses$5,369 
v3.26.3
Leases (Tables)
9 Months Ended
Sep. 30, 2026
Leases [Abstract]  
Schedule of Assets And Liabilities Lessee
The tables below include information about the material operating leases assumed in the Kashiv Acquisition.
September 30, 2026
Weighted-average remaining lease term
7 years
Weighted-average discount rate
6.4%
Schedule of Lessee, Operating Lease, Liability, to be Paid, Maturity
Maturities of lease liabilities assumed as part of the Kashiv Acquisition as of September 30, 2026 were as follows (in thousands):
Operating Leases
Remainder of 2026
$1,839 
20277,349 
20287,061 
20294,230 
20303,064 
Thereafter17,624 
Total lease payments41,167 
Less: Imputed interest8,972 
Total$32,195 
v3.26.3
Acquisition - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 10, 2026
Apr. 21, 2026
Sep. 30, 2026
Sep. 30, 2026
Business Combination [Line Items]        
Contingent consideration     $ 383,000 $ 383,000
Royalties        
Business Combination [Line Items]        
Contingent consideration     248,000 248,000
Kashiv        
Business Combination [Line Items]        
Voting interest acquired (percent)   100.00%    
Expected price of acquisition   $ 375,000    
Consideration paid in common stock (in shares)   28,942,108    
Contingent consideration $ 350,000 $ 350,000 383,000 383,000
Contingent liabilities, percentage   25.00%    
Total purchase price $ 1,302,486      
Acquisition related cost, expense   $ 3,000 19,000 31,700
Revenue     1,200 1,200
Operating loss     $ (28,400) $ (28,400)
Kashiv | Royalties        
Business Combination [Line Items]        
Eligibility period 12 years 12 years    
v3.26.3
Acquisition - Schedule of Preliminary Consideration Transferred (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Aug. 10, 2026
Apr. 21, 2026
Sep. 30, 2026
Sep. 30, 2026
Business Combination [Line Items]        
Contingent consideration     $ 383,000 $ 383,000
Significant Unobservable Inputs (Level 3)        
Business Combination [Line Items]        
Contingent consideration     383,000 383,000
Regulatory Milestones        
Business Combination [Line Items]        
Contingent consideration     135,000 135,000
Royalties        
Business Combination [Line Items]        
Contingent consideration     248,000 248,000
Kashiv        
Business Combination [Line Items]        
Cash consideration $ 266,066      
Equity consideration 491,610      
Fair value of contingent consideration – milestone payments   $ 180,000    
Repayment of certain Kashiv debt obligations 162,180      
Receivable from sellers related to purchase price adjustment (1,814)      
Settlement of pre-existing relationship (4,556)      
Preliminary fair value of consideration transferred 1,302,486      
Expected price of acquisition   375,000    
Estimated closing cash   3,900    
Working capital adjustments   66,700    
Prepayment adjustments   $ 3,500    
Consideration paid in common stock (in shares)   28,942,108    
Contingent consideration $ 350,000 $ 350,000 383,000 383,000
Acquisition related cost, expense   $ 3,000 $ 19,000 $ 31,700
Kashiv | Common Class A        
Business Combination [Line Items]        
Consideration paid in common stock (in shares) 28,900,000      
Consideration paid in common stock (in usd per share) $ 17.88      
Discount for lack of marketability 5.00%      
Kashiv | Regulatory Milestones        
Business Combination [Line Items]        
Fair value of contingent consideration – milestone payments $ 137,000      
Contingent consideration 350,000      
Kashiv | Regulatory Milestones | Significant Unobservable Inputs (Level 3)        
Business Combination [Line Items]        
Contingent consideration 137,000      
Kashiv | Tranche One        
Business Combination [Line Items]        
Contingent consideration 250,000      
Kashiv | Tranche Two        
Business Combination [Line Items]        
Contingent consideration 100,000      
Kashiv | Royalties        
Business Combination [Line Items]        
Fair value of contingent consideration – milestone payments $ 252,000      
Eligibility period 12 years 12 years    
Potential contingent payments (percent) 25.00%      
Kashiv | Royalties | Significant Unobservable Inputs (Level 3)        
Business Combination [Line Items]        
Contingent consideration $ 252,000      
v3.26.3
Acquisition - Schedule of Preliminary Purchase Price Allocation for the Acquisitions (Details) - USD ($)
$ in Thousands
4 Months Ended
Aug. 10, 2026
Sep. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Intangible Asset, Finite-Lived, Acquired [Line Items]        
Goodwill   $ 772,473 $ 595,470 $ 597,436
Kashiv        
Intangible Asset, Finite-Lived, Acquired [Line Items]        
Cash and cash equivalents $ 3,111      
Inventories 22,215      
Prepaid expenses and other current assets 12,034      
Property, plant and equipment 111,584      
Goodwill 179,478      
Intangible assets 1,003,000      
Operating lease right-of-use assets 33,900      
Other assets 14,299      
Total assets acquired 1,379,896      
Long-term debt, net 15,137      
Other long-term liabilities 899      
Total liabilities assumed 77,410      
Preliminary fair value of consideration transferred 1,302,486      
Inventory 6,500      
Property, plant, and equipment 10,900      
Lease terms relative to market 2,000      
Long-term restricted cash 4,100      
Kashiv | Nonrelated Party        
Intangible Asset, Finite-Lived, Acquired [Line Items]        
Operating lease right-of-use assets 26,798      
Accounts payable and accrued expenses 28,838      
Current portion of operating lease liabilities 4,605      
Operating lease liabilities 22,687      
Kashiv | Related Party        
Intangible Asset, Finite-Lived, Acquired [Line Items]        
Related party receivables 234      
Operating lease right-of-use assets 7,143      
Accounts payable and accrued expenses 64      
Current portion of operating lease liabilities 412      
Operating lease liabilities $ 4,768      
v3.26.3
Acquisition - Schedule of Acquired Intangible Assets (Details) - Kashiv - USD ($)
$ in Thousands
Aug. 10, 2026
Sep. 30, 2026
Business Combination [Line Items]    
In-process research and development (“IPR&D”) $ 963,000  
Marketed product rights 40,000  
Fair value of identifiable intangible assets acquired $ 1,003,000  
Weighted-Average Useful Life (in years) 9 years  
Estimated useful life (in years)   5 years
v3.26.3
Acquisition - Schedule of Pro Forma (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Business Combination [Line Items]        
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests $ (21,695) $ 2,369 $ 98,223 $ 36,981
Kashiv        
Business Combination [Line Items]        
Net revenue 862,918 793,555 2,386,897 2,216,607
Net income (loss) 8,411 (22,748) 61,380 (43,119)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests $ (11,351) $ (38,511) $ 13,922 $ (84,498)
v3.26.3
Revenue Recognition - Schedule of Revenue by Major Customers by Reporting Segments (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Customer A        
Concentration Risk [Line Items]        
Concentration risk (as a percent) 25.00% 23.00% 24.00% 24.00%
Customer B        
Concentration Risk [Line Items]        
Concentration risk (as a percent) 16.00% 14.00% 16.00% 15.00%
Customer C        
Concentration Risk [Line Items]        
Concentration risk (as a percent) 21.00% 22.00% 21.00% 21.00%
Customer D        
Concentration Risk [Line Items]        
Concentration risk (as a percent) 7.00% 10.00% 8.00% 9.00%
v3.26.3
Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disaggregation of Revenue [Line Items]        
Net revenue $ 862,684 $ 784,513 $ 2,381,400 $ 2,204,441
Affordable Medicines        
Disaggregation of Revenue [Line Items]        
Net revenue 547,109 460,741 1,460,259 1,308,874
Affordable Medicines | Subtotal dosage forms        
Disaggregation of Revenue [Line Items]        
Net revenue 542,194 454,453 1,442,412 1,299,451
Affordable Medicines | Oral solid        
Disaggregation of Revenue [Line Items]        
Net revenue 207,517 180,460 553,789 537,675
Affordable Medicines | Transdermal        
Disaggregation of Revenue [Line Items]        
Net revenue 68,066 47,599 209,067 131,372
Affordable Medicines | Auto-Injector        
Disaggregation of Revenue [Line Items]        
Net revenue 65,163 78,940 169,289 193,694
Affordable Medicines | Injectable        
Disaggregation of Revenue [Line Items]        
Net revenue 53,805 54,368 160,526 123,802
Affordable Medicines | Biosimilar        
Disaggregation of Revenue [Line Items]        
Net revenue 77,710 17,009 129,139 70,797
Affordable Medicines | Oral liquid        
Disaggregation of Revenue [Line Items]        
Net revenue 9,092 16,415 31,555 57,842
Affordable Medicines | Other dosage forms        
Disaggregation of Revenue [Line Items]        
Net revenue 60,841 59,662 189,047 184,269
Affordable Medicines | International        
Disaggregation of Revenue [Line Items]        
Net revenue 4,915 6,288 17,847 9,423
Specialty        
Disaggregation of Revenue [Line Items]        
Net revenue 150,262 125,240 432,822 361,580
Specialty | Subtotal therapeutic classes        
Disaggregation of Revenue [Line Items]        
Net revenue 148,774 125,240 431,334 361,080
Specialty | Central nervous system        
Disaggregation of Revenue [Line Items]        
Net revenue 96,177 77,631 274,904 228,666
Specialty | Hormonal / allergy        
Disaggregation of Revenue [Line Items]        
Net revenue 43,148 37,685 121,179 107,302
Specialty | Other therapeutic classes        
Disaggregation of Revenue [Line Items]        
Net revenue 9,449 9,924 35,251 25,112
Specialty | License agreement        
Disaggregation of Revenue [Line Items]        
Net revenue 1,488 0 1,488 500
AvKARE        
Disaggregation of Revenue [Line Items]        
Net revenue 165,313 198,532 488,319 533,987
AvKARE | Distribution        
Disaggregation of Revenue [Line Items]        
Net revenue 92,905 96,216 268,984 300,774
AvKARE | Government label        
Disaggregation of Revenue [Line Items]        
Net revenue 53,385 87,755 163,541 183,313
AvKARE | Institutional        
Disaggregation of Revenue [Line Items]        
Net revenue 10,012 5,853 31,943 26,994
AvKARE | Other        
Disaggregation of Revenue [Line Items]        
Net revenue $ 9,011 $ 8,708 $ 23,851 $ 22,906
v3.26.3
Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2026
USD ($)
Contract Charge - Backs and Sales Volume Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period $ 801,186
Provision related to sales recorded in the period 3,161,376
Credits/payments issued during the period (3,427,057)
Balance, end of period 535,505
Cash Discount Allowances  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 40,992
Provision related to sales recorded in the period 107,663
Credits/payments issued during the period (116,413)
Balance, end of period 32,242
Accrued Returns Allowance  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 179,471
Provision related to sales recorded in the period 60,770
Credits/payments issued during the period (48,728)
Balance, end of period 191,513
Accrued Medicaid and Commercial Rebates  
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]  
Balance, beginning of period 119,486
Provision related to sales recorded in the period 135,010
Credits/payments issued during the period (184,184)
Balance, end of period $ 70,312
v3.26.3
Alliance and Collaboration - Schedule of Company’s Alliance and Collaboration Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Orion Corporation | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income $ 3,445   $ 3,445   $ 4,811
Orion Corporation | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 296   296   814
Orion Corporation | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement (776) $ (912) (1,883) $ (2,677)  
Orion Corporation | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement (197) (372) (818) (1,131)  
Zambon Biotech S.A. | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 641   641   0
Zambon Biotech S.A. | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 2,725   2,725   2,530
Zambon Biotech S.A. | Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement 1,488 0 1,488 0  
mAbxience S.L. | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 0   0   7,500
Pfizer Inc. (formerly Metsera, Inc.)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from financing obligations         6,400
Deferred income from manufacturing services         3,000
Pfizer Inc. (formerly Metsera, Inc.) | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 22,415   22,415   9,378
Pfizer Inc. (formerly Metsera, Inc.) | Balance Sheet Location: us-gaap:PrepaidExpenseAndOtherAssetsCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 0   0   $ 321
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:OtherOperatingIncomeExpenseNet          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement 0 0 (6,877) 0  
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement $ 0 $ 245 $ 0 $ 2,218  
v3.26.3
Alliance and Collaboration - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
May 26, 2026
Jan. 30, 2026
Jan. 29, 2026
Apr. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Aug. 10, 2026
May 13, 2026
Pfizer Arrangement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaborative arrangement term (in years)   4 years 7 years              
Pfizer Arrangement | Pfizer Inc. (formerly Metsera, Inc.)                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum potential future construction costs         $ 100,000   $ 100,000      
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:OtherOperatingIncomeExpenseNet                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaborative arrangement license revenue agreement         0 $ 0 (6,877) $ 0    
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaborative arrangement license revenue agreement         $ 0 $ 245 0 $ 2,218    
MSN Laboratories Private Limited Supply and Distribution Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaborative arrangement upfront payment       $ 75,000            
Estimated useful life (in years)       5 years            
Tirzepatide Adalvo License and Supply Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
License supply agreement, potential future milestone payments                   $ 21,000
License supply agreement, potential future milestone payments             $ 3,000      
Denosumab Biosimilar Licensing and Supply Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Estimated useful life (in years)         5 years   5 years      
Collaborative arrangement, signing fee $ 6,000                  
Alvotech hf. License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
License supply agreement, potential future milestone payments                 $ 25,000  
Intas Pharmaceuticals Limited License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
License supply agreement, potential future milestone payments                 $ 23,500  
v3.26.3
Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Tax Disclosure [Abstract]        
Provision for (benefit from) income taxes $ 2,751 $ (23,355) $ 6,303 $ 5,614
Effective tax rate 18.30% 447.20% 3.80% 6.70%
v3.26.3
Income Taxes - Schedule of Tax Receivable Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Income Tax Disclosure [Abstract]          
Increase (decrease) in tax receivable agreement liability $ 12,992 $ (20,808) $ 13,098 $ (5,701)  
Tax receivable agreement liability - short term 16,323   16,323   $ 38,832
Tax receivable agreement liability - long term 15,432   15,432   18,656
Total $ 31,755   $ 31,755   $ 57,488
v3.26.3
Income Taxes - Narrative (Details)
$ in Millions
9 Months Ended
Sep. 30, 2026
USD ($)
Income Tax Disclosure [Abstract]  
Payments for tax receivable agreement $ 38.8
Income tax, liabilities under tax receivable agreement unrecorded $ 116.0
v3.26.3
(Loss) Earnings per Share - Schedule of Basic and Diluted (Loss) Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Numerator:        
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Denominator:        
Weighted-average shares outstanding - basic (in shares) 335,733 314,168 323,724 312,998
Effect of dilutive securities:        
Weighted-average shares outstanding - diluted (in shares) 335,733 324,754 335,233 323,704
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:        
Basic (in dollars per share) $ (0.06) $ 0.01 $ 0.30 $ 0.12
Diluted (in dollars per share) $ (0.06) $ 0.01 $ 0.29 $ 0.11
Stock options        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 882 767 981
Restricted stock units        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 4,129 4,192 4,303
Performance stock units        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 5,575 6,550 5,422
v3.26.3
(Loss) Earnings per Share - Schedule of Securities Excluded from Diluted Earnings (Loss) per Share Computation (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from earnings per share (in shares) 1,153 347 0 347
Restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from earnings per share (in shares) 6,908 0 0 0
Performance stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Potentially dilutive securities excluded from earnings per share (in shares) 6,571 1,960 0 1,960
v3.26.3
Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - Nonrelated Party - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Related Party Transaction [Line Items]    
Gross accounts receivable $ 1,591,921 $ 1,740,324
Allowance for credit losses (7,330) (3,003)
Contract charge-backs and sales volume allowances (535,505) (801,186)
Cash discount allowances (32,242) (40,992)
Subtotal (575,077) (845,181)
Trade accounts receivable, net $ 1,016,844 $ 895,143
v3.26.3
Trade Accounts Receivable, Net - Schedule of Concentration of Receivables (Details) - Accounts Receivable - Customer Concentration Risk
9 Months Ended 12 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Customer A    
Concentration Risk [Line Items]    
Concentration risk (as a percent) 39.00% 39.00%
Customer B    
Concentration Risk [Line Items]    
Concentration risk (as a percent) 25.00% 23.00%
Customer C    
Concentration Risk [Line Items]    
Concentration risk (as a percent) 24.00% 26.00%
v3.26.3
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Inventory Disclosure [Abstract]    
Raw materials $ 286,654 $ 227,353
Work in process 78,098 55,455
Finished goods 343,204 323,494
Total inventories $ 707,956 $ 606,302
v3.26.3
Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Deposits and advances $ 4,812 $ 4,437
Prepaid insurance 6,787 6,723
Prepaid regulatory fees 10,791 8,109
Income and other tax receivables 24,454 18,662
Prepaid taxes 14,482 17,068
Accrued royalty income 84,069 14,332
Other current receivables 9,440 5,295
Chargebacks receivable 7,815 5,972
Other prepaid assets 34,119 17,797
Total prepaid expenses and other current assets $ 196,769 $ 98,395
v3.26.3
Property, Plant, and Equipment, Net - Schedule of Property, Plant, and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment $ 1,206,027 $ 1,049,120
Less: Accumulated depreciation (633,393) (606,170)
Property, plant, and equipment, net 572,634 442,950
Land    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 20,559 19,690
Buildings    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 234,777 234,599
Leasehold improvements    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 153,184 133,833
Machinery and equipment    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 546,778 473,076
Furniture and fixtures    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 17,574 16,170
Vehicles    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 2,282 2,018
Computer equipment    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment 83,100 76,825
Construction-in-progress    
Property, Plant, and Equipment [Line Items]    
Total property, plant, and equipment $ 147,773 $ 92,909
v3.26.3
Property, Plant, and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Property, Plant, and Equipment [Abstract]        
Depreciation $ 14,700 $ 14,500 $ 40,800 $ 43,700
Impairment charges $ 13,800   $ 13,832 $ 0
v3.26.3
Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Goodwill [Roll Forward]    
Beginning, balance of period $ 595,470 $ 597,436
Goodwill acquired during the period 179,478  
Currency translation (2,475) (1,966)
Ending, balance of period 772,473 595,470
Affordable Medicines    
Goodwill [Roll Forward]    
Beginning, balance of period 159,693 161,659
Goodwill acquired during the period 179,478  
Currency translation (2,475) (1,966)
Ending, balance of period 336,696 159,693
Specialty    
Goodwill [Roll Forward]    
Beginning, balance of period 366,312 366,312
Goodwill acquired during the period 0  
Currency translation 0 0
Ending, balance of period 366,312 366,312
AvKARE    
Goodwill [Roll Forward]    
Beginning, balance of period 69,465 69,465
Goodwill acquired during the period 0  
Currency translation 0 0
Ending, balance of period $ 69,465 $ 69,465
v3.26.3
Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]    
Cost $ 1,851,113 $ 1,602,394
Accumulated Amortization (1,148,958) (1,046,996)
Net 702,155 555,398
IPR&D 849,100 8,100
Intangible assets, cost 2,700,213 1,610,494
Intangible assets, net $ 1,551,255 563,498
Product rights    
Intangible Asset, Finite-Lived [Line Items]    
Weighted-Average Amortization Period (in years) 5 years 9 months 18 days  
Cost $ 1,768,413 1,519,694
Accumulated Amortization (1,071,688) (977,819)
Net $ 696,725 541,875
Other intangible assets    
Intangible Asset, Finite-Lived [Line Items]    
Weighted-Average Amortization Period (in years) 1 year 10 months 24 days  
Cost $ 82,700 82,700
Accumulated Amortization (77,270) (69,177)
Net $ 5,430 $ 13,523
v3.26.3
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Aug. 10, 2026
Intangible Asset, Finite-Lived [Line Items]          
Amortization of intangible assets $ 38,600 $ 39,600 $ 103,500 $ 130,600  
Intangible asset impairment charges   $ 22,800 $ 975 $ 22,784  
Intangible Asset, Excluding Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of goods sold   Cost of goods sold  
Kashiv          
Intangible Asset, Finite-Lived [Line Items]          
Intangible assets         $ 1,003,000
Kashiv | IPR&D          
Intangible Asset, Finite-Lived [Line Items]          
Intangible assets         963,000
Product rights | Kashiv          
Intangible Asset, Finite-Lived [Line Items]          
Intangible assets         $ 40,000
v3.26.3
Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Abstract]    
Indefinite-lived intangible assets (excluding goodwill) $ 849,100 $ 8,100
Remainder of 2026 45,026  
2027 162,946  
2028 117,468  
2029 104,765  
2030 105,989  
2031 92,587  
Thereafter 73,374  
Net $ 702,155 $ 555,398
v3.26.3
Other Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Other Assets [Abstract]    
Interest rate swap $ 33,775 $ 5,756
Security deposits 4,811 3,932
Long-term deposits and prepaid expenses 2,437 3,412
Deferred revolving credit facility costs 4,331 5,197
Long-term restricted cash 8,680 2,068
Equipment deposits 48,068 34,332
Other long-term assets 20,705 3,108
Total other assets $ 122,807 $ 57,805
v3.26.3
Accounts Payable and Accrued Expenses (Details) - Nonrelated Party - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Related Party Transaction [Line Items]    
Accounts payable $ 283,662 $ 254,671
Accrued returns allowance 191,513 179,471
Accrued compensation 90,790 79,886
Accrued Medicaid and commercial rebates 70,312 119,486
Accrued royalties 72,981 30,040
Accrued professional fees 20,904 14,514
Accrued interest 8,530 18,663
Accrued other 50,139 64,585
Total accounts payable and accrued expenses $ 788,831 $ 761,316
v3.26.3
Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Aug. 10, 2026
Dec. 31, 2025
Debt Instrument [Line Items]      
Total debt $ 3,050,747   $ 2,694,750
Less: debt issuance costs (111,313)   (122,874)
Total debt, net of debt issuance costs 2,939,434   2,571,876
Less: current portion of long-term debt (23,933)   (6,761)
Total long-term debt, net 2,915,501   2,565,115
Term Loan | Term Loan Due 2032      
Debt Instrument [Line Items]      
Total debt 2,434,263   2,094,750
Senior Notes | Senior Notes Due 2032      
Debt Instrument [Line Items]      
Total debt 600,000   600,000
Term Loan Facility | Kashiv Rupee Term Loan Facility      
Debt Instrument [Line Items]      
Total debt $ 16,484 $ 16,600 $ 0
v3.26.3
Debt - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Oct. 30, 2026
Aug. 05, 2026
Aug. 03, 2026
Jul. 31, 2026
Feb. 02, 2026
Aug. 31, 2026
Feb. 28, 2026
Sep. 30, 2026
May 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Aug. 10, 2026
Dec. 31, 2025
Debt Instrument [Line Items]                              
Loss on refinancing                   $ 5,760 $ 31,365 $ 9,270 $ 31,365    
Incremental term loans               $ 3,050,747   3,050,747   3,050,747     $ 2,694,750
Borrowings on revolving credit facilities                       280,000 $ 218,000    
Term Loan Due 2032 | Term Loan                              
Debt Instrument [Line Items]                              
Decrease in interest rate     0.50%   0.50%                    
Loss on refinancing           $ 2,400 $ 3,500                
Incremental term loans               2,434,263   2,434,263   2,434,263     2,094,750
Term Loan Due 2032 | Term Loan | SOFR                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)     2.50%   3.00%                    
Term Loan Due 2032 | Term Loan | Base Rate                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)     1.50%   2.00%                    
Incremental Term Loan | Term Loan                              
Debt Instrument [Line Items]                              
Loss on refinancing                   3,400   3,400      
Debt incurred                           $ 350,000  
Percentage of outstanding amount used to make quarter principal payments                           0.25%  
2025 Revolving Credit Facility | Revolving Credit Facility                              
Debt Instrument [Line Items]                              
Borrowings on revolving credit facilities   $ 150,000   $ 30,000         $ 100,000            
Repayment of credit facility               100,000              
Outstanding line of credit facility               180,000   180,000   $ 180,000      
2025 Revolving Credit Facility | Revolving Credit Facility | Subsequent Event                              
Debt Instrument [Line Items]                              
Repayment of credit facility $ 50,000                            
2025 Revolving Credit Facility | Line of Credit | SOFR | Revolving Credit Facility                              
Debt Instrument [Line Items]                              
Debt instrument, interest rate floor (percent)                       0.00%      
2025 Revolving Credit Facility | Line of Credit | SOFR | Revolving Credit Facility | Minimum                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)                       1.25%      
2025 Revolving Credit Facility | Line of Credit | SOFR | Revolving Credit Facility | Maximum                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)                       1.50%      
2025 Revolving Credit Facility | Line of Credit | Base Rate | Revolving Credit Facility                              
Debt Instrument [Line Items]                              
Debt instrument, interest rate floor (percent)                       1.00%      
2025 Revolving Credit Facility | Line of Credit | Base Rate | Revolving Credit Facility | Minimum                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)                       0.25%      
2025 Revolving Credit Facility | Line of Credit | Base Rate | Revolving Credit Facility | Maximum                              
Debt Instrument [Line Items]                              
Basis spread on variable rate (as a percent)                       0.50%      
Kashiv Rupee Term Loan Facility | Term Loan Facility                              
Debt Instrument [Line Items]                              
Incremental term loans               $ 16,484   $ 16,484   $ 16,484   $ 16,600 $ 0
Line of credit facility, maximum borrowing capacity                           $ 72,000  
v3.26.3
Other Long-Term Liabilities (Details) - Nonrelated Party - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Other Liabilities [Line Items]    
Long-term compensation $ 9,847 $ 11,354
Deferred income 26,598 7,324
Other long-term liabilities 1,352 13,585
Total other long-term liabilities $ 37,797 $ 32,263
v3.26.3
Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Aug. 10, 2026
Apr. 21, 2026
Dec. 31, 2025
Assets        
Derivative asset $ 33,775     $ 5,756
Liabilities        
Contingent consideration 383,000      
Contingent consideration - related party - short term 59,000     0
Contingent consideration - related party - long term 324,000     0
Related Party | Sellers Of Kashiv        
Liabilities        
Contingent consideration 383,000      
Contingent consideration - related party - short term 59,000      
Contingent consideration - related party - long term 324,000      
Kashiv        
Liabilities        
Contingent consideration 383,000 $ 350,000 $ 350,000  
Quoted Prices in Active Markets (Level 1)        
Assets        
Derivative asset 0     0
Liabilities        
Contingent consideration 0      
Significant Other Observable Inputs (Level 2)        
Assets        
Derivative asset 33,775     5,756
Liabilities        
Contingent consideration 0      
Significant Unobservable Inputs (Level 3)        
Assets        
Derivative asset 0     $ 0
Liabilities        
Contingent consideration $ 383,000      
v3.26.3
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 10, 2026
Apr. 21, 2026
Sep. 30, 2026
Sep. 30, 2026
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration     $ 383,000 $ 383,000
Royalties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration     248,000 248,000
Kashiv Biosciences, LLC        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 350,000 $ 350,000 383,000 383,000
Contingent payments     $ 0 $ 0
Kashiv Biosciences, LLC | Royalties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Potential contingent payments (percent) 25.00%      
Eligibility period 12 years 12 years    
v3.26.3
Fair Value Measurements - Schedule of Reconciliation of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2026
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance, December 31, 2025 $ 0
Addition due to the Kashiv Acquisition 389,000
Change in fair value during period (6,000)
Balance, September 30, 2026 $ 383,000
v3.26.3
Fair Value Measurements - Schedule of Significant Inputs Used in Fair Value Measurements (Details)
$ in Thousands
Sep. 30, 2026
USD ($)
product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair value $ 383,000
Regulatory Milestones  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair value $ 135,000
Regulatory Milestones | Discount rate | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.058
Regulatory Milestones | Discount rate | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.068
Regulatory Milestones | Discount rate | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.062
Regulatory Milestones | Probability of payment | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.202
Regulatory Milestones | Probability of payment | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.925
Regulatory Milestones | Probability of payment | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.630
Royalties  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Fair value $ 248,000
Number of products launched | product 3
Royalties | Discount rate | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.054
Royalties | Discount rate | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.076
Royalties | Discount rate | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.068
Royalties | Volatility | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.250
Royalties | Volatility | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.250
Royalties | Volatility | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.250
Royalties | Probability of payment  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 1
Royalties | Probability of payment | Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.202
Royalties | Probability of payment | Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.925
Royalties | Probability of payment | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.630
Royalties | Projected year of payment, payments discounted, percentage  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input 0.50
v3.26.3
Fair Value Measurements - Schedule of the Company’s Indebtedness at Fair Value (Details) - Level 2 - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Term Loan | Term Loan Due 2032    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value $ 2,446,434 $ 2,115,698
Senior Notes | Senior Notes Due 2032    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Long-term debt fair value $ 601,500 $ 633,000
v3.26.3
Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Jun. 30, 2025
Dec. 31, 2024
Derivative [Line Items]                
Accumulated other comprehensive gain (loss) $ 531,257 $ (109,955) $ 531,257 $ (109,955) $ 33,024 $ (71,329) $ (112,533) $ (109,512)
Unrealized (loss) gain on cash flow hedge, net of tax                
Derivative [Line Items]                
Accumulated other comprehensive gain (loss) 21,905 (18,375) 21,905 (18,375)   (14,844)   $ 6,350
Designated as Hedging Instrument | Unrealized (loss) gain on cash flow hedge, net of tax                
Derivative [Line Items]                
Derivative gain (loss) reclassified from accumulated other comprehensive loss into income (loss) (2,900) $ (4,200) (8,700) $ 1,700        
Accumulated other comprehensive gain (loss) $ 21,900   21,900     $ (14,800)    
Cash flow hedge loss to be reclassified within 12 months     $ 7,600          
v3.26.3
Financial Instruments - Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Fair Value $ 33,775 $ 5,756
v3.26.3
Commitments and Contingencies - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 48 Months Ended
Feb. 26, 2026
USD ($)
case
Jan. 23, 2026
USD ($)
May 07, 2025
USD ($)
Mar. 31, 2026
USD ($)
state
Apr. 30, 2024
USD ($)
$ / twinPack
Sep. 30, 2026
USD ($)
case
state
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
case
state
Sep. 30, 2025
USD ($)
Dec. 31, 2020
complaint
state
Dec. 31, 2019
complaint
state
Dec. 31, 2034
USD ($)
Feb. 25, 2026
case
Dec. 31, 2025
USD ($)
May 15, 2023
Loss Contingencies [Line Items]                              
Charges (credit) related to legal matters, net           $ 6,497 $ 0 $ 15,248 $ (390)            
Current portion of liabilities for legal matters           27,534   27,534           $ 43,256  
Escrow deposit                           24,200  
Forecast                              
Loss Contingencies [Line Items]                              
Payments for legal settlements                       $ 133,500      
Civil Prescription Opioids Settlement Agreement                              
Loss Contingencies [Line Items]                              
Payments for legal settlements $ 12,100 $ 23,800                          
Government Investigations                              
Loss Contingencies [Line Items]                              
Litigation settlement, charges           8,000   8,000              
Current portion of liabilities for legal matters           8,000   8,000           0  
Civil prescription opioid litigation                              
Loss Contingencies [Line Items]                              
Litigation settlement on product               21,200              
Litigation settlement discount on expected payments               20,800              
Current portion of liabilities for legal matters           $ 9,454   $ 9,454           42,271  
Number of cases filed | case 70                       800    
Number of cases filed in MDL and other federal courts | case 24                            
Number of cases filed in state courts | case 42                            
Litigation settlement amount       $ 11,600                      
Litigation settlement agreement terms         10 years                    
Number of states with cases | state       5                      
Civil prescription opioid litigation | Forecast                              
Loss Contingencies [Line Items]                              
Payments for legal settlements                       41,400      
Equal distributions, amount                       $ 10,400      
Civil prescription opioid litigation | Litigation Settlement, Option Two                              
Loss Contingencies [Line Items]                              
Litigation settlement, percentage of product value       25.00% 25.00% 25.00%   25.00%              
Litigation settlement amount         $ 44,400                    
Litigation settlement agreement terms         4 years                    
Civil prescription opioid litigation | Litigation Settlement, Option One                              
Loss Contingencies [Line Items]                              
Litigation settlement amount         $ 92,500                    
Litigation settlement, product supply amount         $ 177,400                    
Litigation settlement, product supply price (in USD per twin pack) | $ / twinPack         125                    
Civil prescription opioid litigation | Litigation Settlement, Option One | Maximum                              
Loss Contingencies [Line Items]                              
Litigation settlement amount         $ 136,900                    
Antitrust class action litigation                              
Loss Contingencies [Line Items]                              
Litigation settlement, charges               $ 7,500              
Current portion of liabilities for legal matters           $ 7,450   $ 7,450           $ 0  
United States Department of Justice Investigations                              
Loss Contingencies [Line Items]                              
Percentage of prescribed label (percent)                             1.00%
Generic Digoxin and Doxycycline Antitrust Litigation                              
Loss Contingencies [Line Items]                              
Number of states, filed civil lawsuit | state                   43 43        
Loss contingency, new claims filed, number | complaint                   2 2        
Ranitidine Litigation                              
Loss Contingencies [Line Items]                              
Number of states with cases | state           4   4              
Number of cases | case           95   95              
Carickhoff v. Amneal Pharmaceuticals Inc., et al.                              
Loss Contingencies [Line Items]                              
Loss contingency, damages sought, value     $ 55,400                        
v3.26.3
Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters $ 27,534 $ 43,256
Civil prescription opioid litigation (Liabilities for legal matters - long term) 71,663 71,819
Civil prescription opioid litigation    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 9,454 42,271
Civil prescription opioid litigation (Liabilities for legal matters - long term) 71,663 71,819
Liability for legal matters 81,100  
Government investigations    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 8,000 0
Antitrust class action litigation    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 7,450 0
Other    
Loss Contingencies [Line Items]    
Current portion of liabilities for legal matters 2,630 $ 985
Nationwide Opioids Settlement Agreement    
Loss Contingencies [Line Items]    
Liability for legal matters 80,600  
Liability to be settled with cash 79,700  
Liability to be settled with products $ 900  
v3.26.3
Commitment and Contingencies - Schedule of Cash Payments (Details)
$ in Thousands
Sep. 30, 2026
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2027 $ 12,670
2028 12,389
2029 12,389
2030 12,389
2031 11,939
2032 to 2034 35,816
Total settlement payments 97,592
Less: imputed interest at a rate of 5.5% (17,917)
Total $ 79,675
Imputed interest rate 5.50%
Cash conversion payments $ 10,400
Aggregate cash conversion payments $ 41,400
v3.26.3
Stockholders’ Equity (Deficiency) - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Stockholders' equity beginning balance $ 33,024 $ (112,533) $ (71,329) $ (109,512)
Other comprehensive (loss) gain before reclassification     18,915 (38,659)
Reclassification of cash flow hedge to earnings, net of tax of $0     8,730 (1,714)
Stockholders' equity ending balance 531,257 (109,955) 531,257 (109,955)
Taxes on reclassification of cash flow hedge to earnings 0 0 0 0
Accumulated other comprehensive loss        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Stockholders' equity beginning balance (100,666) (97,431) (110,729) (65,510)
Stockholders' equity ending balance (83,084) (105,883) (83,084) (105,883)
Foreign currency translation adjustments        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Stockholders' equity beginning balance     (90,545) (71,860)
Other comprehensive (loss) gain before reclassification     (13,332) (15,648)
Reclassification of cash flow hedge to earnings, net of tax of $0     0 0
Stockholders' equity ending balance (103,877) (87,508) (103,877) (87,508)
Unrealized (loss) gain on cash flow hedge, net of tax        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Stockholders' equity beginning balance     (14,844) 6,350
Other comprehensive (loss) gain before reclassification     28,019 (23,011)
Reclassification of cash flow hedge to earnings, net of tax of $0     8,730 (1,714)
Stockholders' equity ending balance 21,905 (18,375) 21,905 (18,375)
Other        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Stockholders' equity beginning balance     (5,340) 0
Other comprehensive (loss) gain before reclassification     4,228 0
Reclassification of cash flow hedge to earnings, net of tax of $0     0 0
Stockholders' equity ending balance $ (1,112) $ 0 $ (1,112) $ 0
v3.26.3
Stockholders’ Equity (Deficiency) - Narrative (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended 9 Months Ended
Oct. 01, 2026
Sep. 15, 2026
Aug. 10, 2026
May 31, 2026
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Apr. 02, 2021
Class of Stock [Line Items]                  
Accretion to redemption value         $ 14,239 $ 14,239      
Cash consideration           400 $ 0    
Non-controlling interests         0 0   $ (535)  
Kashiv Specialty Pharmaceuticals, LLC                  
Class of Stock [Line Items]                  
Voting interest acquired (percent)                 98.00%
Kashiv Acquisition | Common Class A                  
Class of Stock [Line Items]                  
Shares issued in connection with the acquisition of Kashiv (in shares)     28.9            
AvKARE, LLC and R&S                  
Class of Stock [Line Items]                  
Payments for repurchase of redeemable noncontrolling interest   $ 19,800              
Accretion to redemption value         $ 14,200 $ 14,200      
Ownership interest (percent)         65.10% 65.10%      
AvKARE, LLC and R&S | Subsequent Event                  
Class of Stock [Line Items]                  
Payments for repurchase of redeemable noncontrolling interest $ 19,800                
Ownership interest (percent) 66.40%                
Kashiv Specialty Pharmaceuticals, LLC | Related Party                  
Class of Stock [Line Items]                  
Ownership percentage by noncontrolling owners (percent)       2.00%          
Cash consideration       $ 400          
Non-controlling interests       $ 600          
v3.26.3
Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Related Party          
Related Party Transaction [Line Items]          
Related party receivables - short term $ 1,876   $ 1,876   $ 470
Accounts payable and accrued expenses 18,913   18,913   55,485
Related party payables - long term 15,878   15,878   19,132
Kashiv | Related Party          
Related Party Transaction [Line Items]          
Related party receivables - short term 0   0   413
Accounts payable and accrued expenses 0   0   14,980
Kashiv | Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 1,654 $ 3,353 7,533 $ 11,148  
Kashiv | Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 407 3,602 5,042 9,218  
Kashiv | Generic development supply agreement - recognition of deferred income          
Related Party Transaction [Line Items]          
Amounts of transaction with related party (163) 0 (163) 0  
Kashiv | Development and commercialization agreement - Omalizumab          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 22,500 0 22,500  
Kashiv | Generic development supply agreement - research and development material          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 (502) 0 (502)  
Kashiv | Storage agreement          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 (71) 0 (189)  
Kashiv | Development and commercialization agreement - Pegfilgrastim Auto Injector - milestone          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 0 500 3,000  
Kashiv | Development and commercialization agreement - Carfilzomib          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 0 0 2,000  
Kashiv | Parking space lease          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 0 0 25  
Kashiv | Generic development supply agreement - development activity deferred income          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 0 0 (99)  
Members - tax receivable agreement | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 16,323   16,323   38,832
Related party payables - long term 15,432   15,432   18,656
Members - tax receivable agreement | Increase (decrease) in tax receivable agreement liability          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 12,992 (20,808) 13,098 (5,701)  
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 1,640   1,640   1,353
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement | Inventory and cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 5,067 4,634 16,218 15,973  
Sellers Of Kashiv | Related Party          
Related Party Transaction [Line Items]          
Related party receivables - short term 1,814   1,814   0
Sellers Of Kashiv | Change in fair value of contingent consideration          
Related Party Transaction [Line Items]          
Amounts of transaction with related party (6,000) 0 (6,000) 0  
AzaTech Pharma LLC - supply agreement | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 505   505   254
AzaTech Pharma LLC - supply agreement | Inventory and cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 861 185 2,545 2,512  
Kanan, LLC - operating lease | Inventory and cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 654 592 1,938 1,776  
Sutaria Family Realty, LLC - operating lease | Inventory and cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 405 333 1,143 987  
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 314   314   0
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense | Cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 314 0 1,178 0  
Direct Customer Solutions, LLC | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 57   57   0
Direct Customer Solutions, LLC | Selling, general and administrative          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 166 0 295 0  
Twenty NEA, LLC | Cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 104 0 104 0  
Tracy Properties LLC - operating lease | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 0   0   26
Tracy Properties LLC - operating lease | Selling, general and administrative          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 81 152 248 478  
Avtar Investments LLC - consulting services | Related Party          
Related Party Transaction [Line Items]          
Accounts payable and accrued expenses 74   74   40
Avtar Investments LLC - consulting services | Selling, general and administrative          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 34 0 34 0  
Avtar Investments LLC - consulting services | Research and development          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 60 60 180 180  
AvPROP, LLC - operating lease | Selling, general and administrative          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 48 46 130 150  
Land purchase from family members of the Co-Chief Executive Officers | Related Party          
Related Party Transaction [Line Items]          
Related party payables - long term 446   446   476
Land purchase from family members of the Co-Chief Executive Officers | Property, plant and equipment          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 0 0 11,289  
Tracy Properties LLC | Research and development          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 338 0 6,046  
R&S Solutions - equipment purchase | Property, plant and equipment          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 47 0 207  
Alkermes Plc | Inventory and cost of goods sold          
Related Party Transaction [Line Items]          
Amounts of transaction with related party 0 $ 3 0 $ 67  
AzaTech Pharma LLC | Related Party          
Related Party Transaction [Line Items]          
Related party receivables - short term 62   62   56
Apace Packaging, LLC - packaging agreement | Related Party          
Related Party Transaction [Line Items]          
Related party receivables - short term $ 0   $ 0   $ 1
v3.26.3
Related Party Transactions - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
May 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Aug. 10, 2026
Apr. 21, 2026
Dec. 31, 2025
Oct. 31, 2022
Related Party Transaction [Line Items]                  
Cash consideration       $ 400 $ 0        
Contingent consideration   $ 383,000   383,000          
Contingent consideration - related party - short term   59,000   59,000       $ 0  
Contingent consideration long term   324,000   324,000       0  
Kashiv                  
Related Party Transaction [Line Items]                  
Contingent consideration   383,000   383,000   $ 350,000 $ 350,000    
Related Party                  
Related Party Transaction [Line Items]                  
Accounts payable and accrued expenses   18,913   18,913       55,485  
Related Party | Kashiv Specialty Pharmaceuticals, LLC                  
Related Party Transaction [Line Items]                  
Ownership percentage by noncontrolling owners (percent) 2.00%                
Cash consideration $ 400                
Direct Customer Solutions, LLC | Related Party                  
Related Party Transaction [Line Items]                  
Accounts payable and accrued expenses   57   57       0  
Direct Customer Solutions, LLC | Selling, general and administrative                  
Related Party Transaction [Line Items]                  
Amounts of transaction with related party   166 $ 0 295 0        
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense | Related Party                  
Related Party Transaction [Line Items]                  
Accounts payable and accrued expenses   314   314       $ 0  
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense | Affiliated Entity                  
Related Party Transaction [Line Items]                  
Accounts payable and accrued expenses   $ 300   $ 300          
Ownership interest (percent)   50.00%   50.00%         50.00%
Royalty expense   $ 300   $ 1,200          
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense | Cost of goods sold                  
Related Party Transaction [Line Items]                  
Amounts of transaction with related party   314 $ 0 1,178 $ 0        
Sellers Of Kashiv | Related Party                  
Related Party Transaction [Line Items]                  
Receivable   1,800   1,800          
Contingent consideration   383,000   383,000          
Contingent consideration - related party - short term   59,000   59,000          
Contingent consideration long term   $ 324,000   $ 324,000          
v3.26.3
Segment Information - Narrative (Details)
9 Months Ended
Sep. 30, 2026
segment
Segment Reporting [Abstract]  
Number of reportable segments 3
v3.26.3
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Net revenue $ 862,684 $ 784,513 $ 2,381,400 $ 2,204,441
Cost of goods sold 528,566 510,539 1,392,661 1,388,323
Gross profit 334,118 273,974 988,739 816,118
Selling, general and administrative 139,645 137,815 427,227 380,369
Research and development 68,374 63,352 145,774 151,356
Intellectual property legal development expenses 2,193 2,437 5,822 6,221
Acquisition and integration costs 22,320 0 35,073 0
Restructuring and other charges 936 143 2,140 1,738
Change in fair value of contingent consideration (6,000) 0 (6,000) 0
Charges for property losses and associated expenses 5,369 0 5,369 0
Charges (credit) related to legal matters, net 6,497 0 15,248 (390)
Other operating income (631) (117) (8,870) (5,239)
Operating income 95,415 70,344 366,956 282,063
Affordable Medicines        
Segment Reporting [Line Items]        
Net revenue 547,109 460,741 1,460,259 1,308,874
AvKARE        
Segment Reporting [Line Items]        
Net revenue 165,313 198,532 488,319 533,987
Operating Segments | Affordable Medicines        
Segment Reporting [Line Items]        
Net revenue 547,109 460,741 1,460,259 1,308,874
Cost of goods sold 352,331 280,463 867,459 775,742
Gross profit 194,778 180,278 592,800 533,132
Selling, general and administrative 32,097 37,173 115,782 105,114
Research and development 63,418 55,124 129,727 128,003
Intellectual property legal development expenses 2,138 2,378 5,633 6,069
Acquisition and integration costs 0   0  
Restructuring and other charges 891 90 891 773
Change in fair value of contingent consideration (6,000)   (6,000)  
Charges for property losses and associated expenses 5,334   5,334  
Charges (credit) related to legal matters, net 5,500   14,251 (390)
Other operating income (631) (117) (8,870) (5,239)
Operating income 92,031 85,630 336,052 298,802
Operating Segments | Specialty        
Segment Reporting [Line Items]        
Net revenue 150,262 125,240 432,822 361,580
Cost of goods sold 46,212 73,808 137,497 182,686
Gross profit 104,050 51,432 295,325 178,894
Selling, general and administrative 36,969 33,580 111,755 94,872
Research and development 4,956 8,228 16,047 23,353
Intellectual property legal development expenses 55 59 189 152
Acquisition and integration costs 0   0  
Restructuring and other charges 0 0 347 471
Change in fair value of contingent consideration 0   0  
Charges for property losses and associated expenses 35   35  
Charges (credit) related to legal matters, net 1,000   1,000 0
Other operating income 0 0 0 0
Operating income 61,035 9,565 165,952 60,046
Operating Segments | AvKARE        
Segment Reporting [Line Items]        
Net revenue 165,313 198,532 488,319 533,987
Cost of goods sold 130,023 156,268 387,705 429,895
Gross profit 35,290 42,264 100,614 104,092
Selling, general and administrative 17,919 15,234 51,512 46,007
Research and development 0 0 0 0
Intellectual property legal development expenses 0 0 0 0
Acquisition and integration costs 0   0  
Restructuring and other charges 0 0 0 0
Change in fair value of contingent consideration 0   0  
Charges for property losses and associated expenses 0   0  
Charges (credit) related to legal matters, net 0   0 0
Other operating income 0 0 0 0
Operating income 17,371 27,030 49,102 58,085
Corporate and Other        
Segment Reporting [Line Items]        
Net revenue 0 0 0 0
Cost of goods sold 0 0 0 0
Gross profit 0 0 0 0
Selling, general and administrative 52,660 51,828 148,178 134,376
Research and development 0 0 0 0
Intellectual property legal development expenses 0 0 0 0
Acquisition and integration costs 22,320   35,073  
Restructuring and other charges 45 53 902 494
Change in fair value of contingent consideration 0   0  
Charges for property losses and associated expenses 0   0  
Charges (credit) related to legal matters, net (3)   (3) 0
Other operating income 0 0 0 0
Operating income $ (75,022) $ (51,881) $ (184,150) $ (134,870)
v3.26.3
Segment Information - Schedule of Selling, General and Administrative Expenses on a Departmental Basis (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total $ 139,645 $ 137,815 $ 427,227 $ 380,369
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 1,658 1,089 4,303 3,908
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 13,315 10,972 38,188 32,635
Product marketing 10,231 11,273 32,039 29,168
Commercial operations and salesforce 12,951 9,769 38,326 29,347
Other 472 1,566 3,202 3,722
Total $ 36,969 $ 33,580 $ 111,755 $ 94,872
v3.26.3
Segment Information - Schedule of Research and Development Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total $ 68,374 $ 63,352 $ 145,774 $ 151,356
Affordable Medicines | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 12,343 13,905 37,382 42,139
Materials and supplies 6,944 6,230 24,555 22,865
Product development and studies 127 673 963 1,360
In-licensing and upfront milestones 0 22,500 4,000 29,100
Facilities costs 1,654 1,755 4,623 5,182
Regulatory fees 704 2,317 4,432 4,834
Kashiv R&D expenses 19,421 0 19,421 0
Other 22,225 7,744 34,351 22,523
Total 63,418 55,124 129,727 128,003
Affordable Medicines | Orion Corporation        
Segment Reporting [Line Items]        
Product development and studies (1,000) 1,300 (2,700) 3,800
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits 1,658 1,089 4,303 3,908
Materials and supplies 842 1,358 1,924 2,011
Product development and studies 1,715 2,823 7,108 7,513
In-licensing and upfront milestones 0 0 0 3,000
Facilities costs 45 409 110 1,894
Regulatory fees 0 0 0 0
Kashiv R&D expenses 0 0 0 0
Other 696 2,549 2,602 5,027
Total 4,956 8,228 16,047 23,353
Specialty | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense        
Segment Reporting [Line Items]        
Employee compensation and benefits $ 13,315 $ 10,972 $ 38,188 $ 32,635
v3.26.3
Property Losses and Associated Expenses - Narrative (Details) - Water Damage at India Facility
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 25, 2026
facility
Sep. 30, 2026
USD ($)
Sep. 30, 2026
USD ($)
Unusual or Infrequent Item, or Both [Line Items]      
Number of facilities damaged | facility 1    
Charges for property losses and associated expenses | $   $ 5,369 $ 5,369
v3.26.3
Property Losses and Associated Expenses - Schedule of Property Losses and Associated Expenses (Details) - Water Damage at India Facility - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2026
Unusual or Infrequent Item, or Both [Line Items]    
Total property losses and associated expenses $ 5,369 $ 5,369
Impairment of equipment    
Unusual or Infrequent Item, or Both [Line Items]    
Total property losses and associated expenses 461 461
Impairment of inventory    
Unusual or Infrequent Item, or Both [Line Items]    
Total property losses and associated expenses 4,574 4,574
Repairs and maintenance and other expenses    
Unusual or Infrequent Item, or Both [Line Items]    
Total property losses and associated expenses $ 334 $ 334
v3.26.3
Leases - Narrative (Details) - Kashiv
$ in Thousands
Aug. 10, 2026
USD ($)
Lessee, Lease, Description [Line Items]  
Operating lease right-of-use assets $ 33,900
Current portion of operating lease liabilities 32,500
Related Party  
Lessee, Lease, Description [Line Items]  
Operating lease right-of-use assets 7,143
Current portion of operating lease liabilities $ 5,200
v3.26.3
Leases - Schedule of Term and Discount Rate Information (Details) - Kashiv
Sep. 30, 2026
Lessee, Lease, Description [Line Items]  
Weighted average remaining lease term (in years) 7 years
Weighted average discount rate (as a percent) 6.40%
v3.26.3
Leases - Schedule of Maturities of Lease Liabilities (Details) - Kashiv
$ in Thousands
Sep. 30, 2026
USD ($)
Lessee, Lease, Description [Line Items]  
Remainder of 2026 $ 1,839
2027 7,349
2028 7,061
2029 4,230
2030 3,064
Thereafter 17,624
Total lease payments 41,167
Less: Imputed interest 8,972
Total $ 32,195
v3.26.3
Subsequent Events (Details) - USD ($)
$ in Thousands
2 Months Ended
Oct. 30, 2026
Oct. 01, 2026
Sep. 15, 2026
Sep. 30, 2026
Oct. 05, 2026
Manufacturing And Warehouse Facility          
Subsequent Event [Line Items]          
Lease agreement       10 years  
Total future undiscounted lease payments under leases not yet commenced       $ 49,600  
AvKARE, LLC and R&S          
Subsequent Event [Line Items]          
Payments for repurchase of redeemable noncontrolling interest     $ 19,800    
Ownership interest (percent)       65.10%  
2025 Revolving Credit Facility | Revolving Credit Facility          
Subsequent Event [Line Items]          
Repayment of credit facility       $ 100,000  
Outstanding line of credit facility       $ 180,000  
Subsequent Event | Corporate Headquarters          
Subsequent Event [Line Items]          
Total future undiscounted lease payments under leases not yet commenced         $ 19,900
Subsequent Event | AvKARE, LLC and R&S          
Subsequent Event [Line Items]          
Payments for repurchase of redeemable noncontrolling interest   $ 19,800      
Ownership interest (percent)   66.40%      
Subsequent Event | 2025 Revolving Credit Facility | Revolving Credit Facility          
Subsequent Event [Line Items]          
Repayment of credit facility $ 50,000        
Subsequent Event | Term Loan Facility | Kashiv Rupee Term Loan Facility          
Subsequent Event [Line Items]          
Repayments of debt   $ 16,500